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Proof-of-concept for the generation of a bioengineered heart muscle (BHM) directly from 
human pluripotent stem cells (hPSCs) as a model to simulate human heart muscle development 
was introduced recently by our lab. BHMs undergo stage-specific directed differentiation and 
self-assembly guided by the sequential addition of growth factors and small molecules to 
support (1) mesoderm induction (3 days), (2) cardiac specification (10 days) and (3) cardiac 
maturation (up to 50 days studied). By culture day 22, initial  findings revealed homogeneously 
contracting BHMs with robust inotropic responses to increasing extracellular calcium and β–
adrenergic stimulation. In this thesis, a detailed characterization on the molecular, cellular and 
functional level revealed that BHMs (1) do indeed traverse through defined in-utero like 
developmental stages with characteristic transcriptome profiles, (2) are composed of mainly 
mesodermal cells (cardiomyocytes and fibroblast-like cells), (3) display continuous functional 
maturation over time with enhanced contractile performance on the cellular level and (4) 
develop in late cultures (day 60) a functional neural crest component with resemblance to the 
cardiac sympathetic nervous system. Assessments of drug responses revealed the utility of BHM 
in disease modeling and drug screening. Modulation of one of the pivotal signaling pathways 
implicated in early cardiac induction, such as the BMP pathway during BHM development 
revealed that low concentrations of BMP4 are needed for the optimal differentiation of hPSCs to 
both cardiomyocytes and fibroblast-like cells. In a first effort to reduce all protein stimuli from 
the BHM culture format, screening for BMP4 replacements was performed and identified two 
hit molecules (4’-hydroxychalcone and 4-fluoro-4’-methoxychalcone). Both successfully 
induced cardiac differentiation in monolayer culture when added as BMP4 replacements, but not 
in the BHM culture format. Collectively, this is the first detailed characterization of a novel 
cardiac organoid model (BHM), generated by a single step tissue engineering approach directly 
from hPSCs, with organotypic contractile functionality. Applications in drug screening and 
disease modeling are demonstrated. Further improvements may be achieved by the replacement 
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Congenital heart defects (CHDs) are the leading cause of birth-related deaths affecting 12-
14/1000 births in the Western industrialized world (Hoffman and Kaplan, 2002). The anatomical 
malformations may affect the walls, chambers or adjacent blood vessels. The etiology of most 
CHDs is unknown with approximately 20% being attributed to genetic mutations. Modeling of 
human embryonic cardiogenesis in vitro may help to go in mechanistic insight in early cardiac 
developmental events including events causing cardiac malformations. 
 
The discovery of human embryonic stem (hES) cells (Thomson et al., 1998) and human induced 
pluripotent stem (hIPS) cells (Takahashi et al., 2007; Yu et al., 2007) has revolutionized our 
toolkit to study embryogenesis and subsequent organogenesis and significant effort has been 
invested in improving methods for efficient and reproducible stem cell differentiation towards a 
cardiac lineage. 
 
2.1 Embryonic Heart Development 
 
2.1.1 Morphological changes during heart development 
 
Five days post fertilization, the blastocyst is formed, containing the inner cell mass from which 
the embryo arises, and the trophoblast (an outer layer of cells that later forms the 
syncytiotrophoblast to support the implantation of the embryo into the uterine wall). The 
proliferation of cells within the inner cell mass gives rise to the hypoblast and the epiblast; the 
former forms the yolk sac which does not contribute to any part of the newborn while the latter 
splits to separate the embryonic epiblast from the amniotic ectoderm. The formed amniotic 
cavity is then filled with amniotic fluid which is thought to operate as a “shock absorber” for the 
developing embryo (Gilbert, 2000). The embryonic plate initially known as the bilaminar germ 
disc is oval-shaped and situated between the yolk sac and the amnionic cavity (Fig. 1A). In the 
middle of this disc, the primitive streak that originated from the anterior epiblast is found with a 
rounded node (Hensen’s node) at its cranial end (Moorman et al., 2003). Formation of this 







Figure 1: The gastrulation process. 
(A) The embryonic plate initially known as the bilaminar germ disc is oval-shaped and situated between the yolk 
sac and the amnionic cavity. In the middle of this disc, the primitive streak that originated from the anterior epiblast 
is found with a rounded node (Hensen’s node) at its cranial end. Gastrulation begins at the posterior end of the 
embryo, when epiblast cells migrate through the primitive streak. (B) Formation of the primary germ layers after 
gastrulation. Image taken from Gilbert (2000). 
 
In humans, this process commences around the third week post-fertilization when the embryonic 
epiblast cells migrate through the streak and form the three germ layers: the ectoderm, the 
mesoderm and the endoderm. The first wave of cells migrating through the streak displaces the 
hypoblast cells and forms the endoderm which gives rise to the future gut derivatives (such as 
gastro-intestinal tract, lung and liver). The second wave of cells populates the mesodermal layer 
which is situated between the endoderm and upper layer of the epiblast (Fig. 1B). The 
mesoderm spreads laterally and cranially within the newly formed tri-laminar embryonic disc 
ultimately giving rise to three subpopulations: (1) the paraxial mesoderm as precursors for the 
somites, bone and cartilage, (2) intermediate mesoderm as precursors for the reproductive 
system and kidney and (3) the lateral plate mesoderm as precursors for blood, smooth muscle, 
heart and spleen. The remaining epiblast cells form the ectoderm which will form the surface 
ectoderm (epidermis) and the neural ectoderm (such as sensory organs, neural tube and neural 
crest). 
 
With the formation of the lateral plate mesoderm, the cells migrate cranially and laterally to 





disc. As the ectoderm transforms to a folded neural tube which will give rise to the developing 
brain coupled with invagination of the endoderm to form the foregut, the heart field precursors 
move ventrally and also fold into the primary endocardial tube of the heart enveloped by a 
myocardial epithelium (Harvey, 2002; Moorman et al., 2003). Note that the folding inverts the 
orientation of the developing heart, taking the shape of an inverted “Y” with the inflow region 
located caudally and the outflow region positioned cranially (Fig. 2). Next, the linear tube 
elongates as second heart field cells derived from the cardiac crescent populate both poles of the 
tube forming cranially the outflow tract (Takasato et al., 2014) and the primordium of the right 
ventricle and caudally the sinus venosus (Uhlen et al., 2015), which later becomes associated 
with the newly incorporated primary atrium (Kelly et al., 2001; Mjaatvedt et al., 2001; Waldo et 
al., 2001). The extensive elongation of the tube causes the developing heart to adopt a spiral 
shape and sweep rightwards in a process termed cardiac looping. This, in turn, forces the atria to 
migrate cranially and ultimately become positioned above the ventricles. 
 
By human embryonic day 32, the heart tube is composed of atrial and ventricular components 
along with an outflow tract after which complex remodeling and heart division by septation and 
valve development forms the four-chambered heart; briefly, endocardial cushions arise which 
are precursors of the various valves of the adult heart (bicuspid and tricuspid valves in the 
atrioventricular canal as well as the aortic and pulmonary valves). These cushions also divide 
the outflow tract into the aorta and pulmonary artery via the aorticopulmonary septum (Harvey, 
2002). Other features of remodeling involve the projection of a spongi-like layer of myocytes 
also known as trabeculae carneae from the inner surface of the ventricles along with the fusion 
of the inter-atria and inter-ventricular septae with the atrioventricular septum therefore forming 
the definitive cardiac chambers. This complex nature of cardiac development (differentiation 
and morphogenesis) poses the need to address the fundamental molecular determinants 







Figure 2: Overview of the formation of the four-chambered heart.  
The cardiac crescent is formed from the first and second heart fields (FHF and SHF, respectively) at the end of 
gastrulation. Differentiation of FHF progenitors forms the linear heart tube, which gives rise to the left ventricle and 
a part of the atria. Meanwhile, SHF progenitors contribute to the formation of the right ventricle and the outflow 
tract. The extensive elongation of the tube causes cardiac looping which forces the atria to migrate cranially and 
ultimately become positioned above the ventricles. Complex remodeling and heart division by septation and valve 
development forms the four-chambered heart. Key gene regulators governing this complex process are listed. LA: 
left atria; LV: left ventricle; OFT: outflow tract; RA: right atrium; RA: right atrium; SV: sinus venosus. Image 
taken from Paige et al. (2015). 
 
2.1.2 Molecular changes during heart development 
 
As aforementioned, shortly after gastrulation the three primary germ layers form the endoderm, 
ectoderm and mesoderm (Fig. 1). Studies in mice have shown that cells from the primitive 
streak, marked by the T-box transcription factor T (Brachyury), migrate through the anterior 
sections of the streak to generate cardiac mesoderm (Murry and Keller, 2008). These precursor 
cells express the basic helix-loop-helix transcription factor mesoderm posterior 1 (Mesp1) 
(Bondue et al., 2008; Burridge et al., 2012), which is in turn activated by the expression of the 
T-box transcription factor Eomesodermin (Costello et al., 2011; Paige et al., 2015; van den 
Ameele et al., 2012). Being the master switch for early cardiac specification, the transient 





NK2 homeobox 5 (Nkx2-5), myocyte enhancer factor 2C (Mef2c), heart and neural crest 
derivatives expressed 2 (Hand2), and GATA binding protein 4 (Gata4). It also appears to be 
involved in the downregulation of genes implicated in either maintaining pluripotency such as 
octamer-binding transcription factor 4 (Oct4) and nanog homeobox (Nanog) or in other 
endodermal cell fate determination such as SRY (sex determining region Y)-box 17 (Sox17) and 
forkhead box A2 (Foxa2) (Bondue et al., 2008; Paige et al., 2015). 
 
Mesp1 is only transiently expressed as an early cardiac fate regulator. Subsequently, cardiac 
progenitor cells continue to migrate and form the cardiac crescent with the expression of T-box 
transcription factor (Tbx) 5 and hyperpolarization activated cyclic nucleotide gated potassium 
channel 4 (Hcn4), marking the first heart field (FHF) cells (Liang et al., 2013; Takeuchi et al., 
2003). Conversely, Islet LIM homeodomain 1 (Isl1) labels the second heart field (SHF) cells 
(Cai et al., 2003; Kelly, 2012). The elongation of the linear heart tube via the addition of SHF-
precursors to both poles appears to be primarily mediated by Tbx1 expression (Rana et al., 
2014), which in turn activates fibroblast growth factors (Fgf) 3, 8 and 10 (Park et al., 2006; 
Watanabe et al., 2012; Zaffran and Kelly, 2012). 
 
Following the formation of the primitive heart tube, cardiac chamber morphogenesis and 
specification is induced. This is regulated by multiple transcription factors including Nkx2-5, 
Gata4 and in a narrower pattern the T-box family; briefly, Tbx2 and Tbx3 are expressed in the 
outflow tract and atrioventricular canal (Rana et al., 2013). Tbx5 has a peak expression in the 
inflow tract and primitive atrium (Bruneau et al., 1999). It has been shown to interact with 
Tbx20 (Hoogaars et al., 2007) and other cardiac transcription factors to promote induction of 
atrial natriuretic factor (Nppa) and gap junction proteins connexin 40 and 43 (Cx40 and Cx43 
respectively). With further myocardial chamber specification, myosin light chain (Mlc) 2a and 
2v are transcribed marking the atria and ventricles, respectively (Small and Krieg, 2004), along 
with other cardiac structural proteins such as α-actinin, α-myosin heavy chain (α-MHC), or 
cardiac Troponin-T (cTnT) (Mummery et al., 2012). 
 
The information obtained from embryonic heart development, turned out to be instrumental for 
the development of protocols to direct differentiation of pluripotent stem cells to 





2.2 Directed Cardiac Differentiation of Stem Cells 
 
After the first report on the isolation and culture of hES cells in 1998 (Thomson et al., 1998), it 
was demonstrated that hES would spontaneously differentiate in suspension to embryoid bodies 
(EBs), containing in ~8% of the EBs beating cardiomyocytes (Kehat et al., 2001). Currently, 
two approaches are widely utilized for the cardiac differentiation of hES cells (Fig. 3): (1) 
differentiation in EB comprised typically of defined cell numbers or (2) 2-dimensional (2D) 
cultures (Burridge et al., 2012). The low cardiomyocyte yield is a key limitation of the EB 
protocol and cultures containing 20% fetal bovine serum (FBS) (Kehat et al., 2001). The 
differentiation efficiency improved up to 50% with the addition of growth factors such as bone 
morphogenetic protein (BMP)-4 (Takei et al., 2009) or wingless-type (Wnt)-3A (Tran et al., 







Figure 3: Current methods to differentiate of hPS cells.  
Overview includes the cell culture and differentiation format with the addition of cardiac induction and 
specification factors. (A) Suspension of EBs; (B) forced aggregation of EBs; (C) monolayer differentiation. KSR: 
knock serum replacement; FGF2: fibroblast growth factor-2; BMP4: bone morphogenetic protein 4; VEGF A: 
vascular endothelial growth factor A; DKK1: dickkopf homolog 1; SB431542: TGFβ-1/Activin/NODAL signaling 
inhibitor [ALK4,5,7]; dorsomorphin: BMP signaling inhibitor [ALK2,3,6]; IWR-1: inhibitor of Wnt response-1; 
MEF CM: mouse embryonic fibroblast conditioned hESC medium; RPMI1640: rosewell park memorial institute 
1640 basal medium; B27: media supplement; NOGGIN: BMP signaling inhibitor; Rai: retinoic acid signaling 
inhibitor; LIAPEL: low insulin albucult polyvinyl alcohol essential lipids media; SCF: stem cell factor KITLG; 
LIBEL: low insulin bovine serum albumin essential lipids media; Y27632: rho kinase inhibitor; CHIR99021: GSK3 
inhibitor; IWP-2: inhibitor of Wnt production-2; FBS: fetal bovine serum; DMEM: dulbecco’s modified eagle’s 
medium; RPMI+PVA: RPMI based media supplemented with polyvinyl alcohol; RPMI-INS: RPMI based media 
without insulin. Image adapted from Burridge et al. (2012). 
 
 
Determining the effect and timing of various growth factors on cardiac differentiation was 
further studied in serum free culture using the EB-based approach. The addition of low 
concentrations of BMP4, FGF-2 and Activin-A for mesodermal induction followed by cardiac 
specification with vascular endothelial growth factor (VEGF)-A and dickkopf Wnt signaling 
pathway inhibitor 1 (DKK1) produced contracting cardiomyocyte population whilst maintained 
under hypoxic conditions (Yang et al., 2008). The subsequent inhibition of TGFβ/Activin/Nodal 
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and BMP signaling using small molecules (between day 3-day 5) or Wnt-inhibition (between 
day 4-day 10) enhanced the protocol (Fig. 3A) (Kattman et al., 2011; Willems et al., 2011). 
Another protocol introducing the forced-aggregation method followed by mesoderm induction 
using BMP4 and FGF-2 also increased the efficiency of cardiac differentiation to more than 
90% (Burridge et al., 2011). In a recent attempt to generate a homogeneous population of 
ventricular cardiomyocytes without genetic manipulation or cell sorting, chemical modulation of 
Wnt signaling using inhibitor of Wnt response (IWR)-1 increased expression of cardiac specific 
marker troponin T type 2 (TNNT2) to 89% coupled with a 56-fold increase in MLC2v 
expression (Karakikes et al., 2014) in comparison to the DKK1-treated cells as described by 
Yang et al. (2008). 
 
Culturing cells in monolayer has also been employed to reduce the complex microenvironment 
of EBs (Fig. 3C). The relatively uniform layer of cells permits better control of spatial cell 
arrangement (Hudson et al., 2012), and decreases diffusion barriers. Thus, the addition of 
growth factors and other interventions will have greater control and reproducibility (Mummery 
et al., 2012). This was effective in H7-hES cells that generated >70% cardiomyocytes relative to 
30% with the EB-based approach when exposed to Activin-A and BMP4 in serum-free 
conditions (Paige et al., 2010). The inhibition of Wnt signaling enhanced cardiac specification to 
primitive streak cells in monolayer (2D) culture compared to EB differentiation (Hudson et al., 
2012). Moreover, in an attempt to decrease line to line variability, the same group has shown 
that single-cell culture of hES in a defined medium (mTeSR-1) allowed higher efficiency of 
cardiac differentiation (Hudson et al., 2012). 
 
Despite improved differentiation efficiency, it was the use of defined differentiation protocols 
following known in vivo developmental pathways which has led to robust and efficient cardiac 
differentiation protocols free from contaminating cell types (Murry and Keller, 2008). This is 
highlighted by the importance of Activin-A to switch cell fate to a mesodermal lineage instead 
of to a definitive endodermal lineage when introduced at low concentrations. Concurrently, 







Currently known differentiation methodologies all report spontaneously beating areas composed 
of stem cell-derived cardiomyocytes with an immature phenotype on the morphological, 
molecular and functional levels (Rajala et al., 2011). The structural architecture reveals cells to 
be rarely elongated to a rod-shaped morphology, being the typical phenotype of adult 
cardiomyocytes (Snir et al., 2003). Despite showing sarcomeres with A-, I- and Z-bands and 
intercalated discs with gap junctions analogous to the adult cardiac cells, the sarcomeric 
organization remained immature (Snir et al., 2003) with a highly heterogeneous degree of 
myofibril bundle organization (Kehat et al., 2001). On the molecular level, the stem cell-derived 
cardiomyocytes reveal expression of transcription factors, including Nkx2.5, GATA-4, Isl-1 as 
well as structural proteins, including cardiac troponins T and I, α-actinin, MHC, MLC2a and 
MLC2v which suggests the presence of a mixture of ventricular and atrial-like cardiac cells with 
diverse ratios depending on the differentiation protocol utilized (Hudson et al., 2012; Kehat et 
al., 2001; Norstrom et al., 2006; Yoon et al., 2006). 
 
Stem cell-differentiated cardiomyocytes reveal immature action potentials (AP) characterized by 
lower upstroke velocity and automaticity (He et al., 2003; Rajala et al., 2011). The absence of an 
inward rectifier potassium current, as detected with global expression profiling, may explain 
their spontaneous contractility (Xu et al., 2009). Voltage clamp studies also support these 
observations (Brito-Martins et al., 2008). Irregular intracellular calcium handling may be 
explained by the lack of phospholamban and calsequestrin proteins in the sarcoplasmic 
reticulum (Binah et al., 2007; Dolnikov et al., 2005; Sartiani et al., 2007). Additionally, hES-
derived cardiomyocytes display a negative force-frequency relationship as opposed to native 
adult myocytes (Kehat et al., 2002). 
 
Additional research is needed to develop strategies for enhancing the maturity of stem cell-
derived cardiomyocytes in vitro. Several groups suggested the use of tissue engineering to better 







2.3 Tissue Engineering: Basis for Modeling Heart Development in a Dish 
 
Tissue engineering has many potential applications, including organ repair, disease modeling 
and drug development. The first macroscopic engineered myocardium was constructed using 
embryonic chick cardiomyocytes mixed with a collagen hydrogel and utilized as a test bed for 
genetic manipulation (Eschenhagen et al., 1997). Matrigel
TM
 for the provision of additional 
extracellular matrix components and the application of mechanical strain were identified as 
essential factors for the translation of the avian to a mammalian model of engineered heart 
muscle (Zimmermann et al., 2000). Other tissue engineering approaches include cardiac cell 
seeding on preformed scaffolds (Carrier et al., 1999) and stacking of myocyte sheets to form a 
multi-layered muscle (Shimizu et al., 2002) (Fig. 4). 
 
Ideally, these engineered tissues should mimic the native myocardial environment. A key 
feature of advanced myocardial tissue engineering formats is their anisotropic contractile 
performance. This is typically coupled with advanced sarcomere organization and longitudinal 
cardiomyocyte orientation in comparison to EB and 2D cultures. Enhanced maturation of 
neonatal rat cardiomyocyte-based engineered heart muscle (EHM) was evidenced by a shift 
from skeletal to the cardiac actin isoform alongside MLC2v expression (Tiburcy et al., 2011). 
The presence of non-myocytes in EHM was found to be important for advanced functional 
maturation (Naito et al., 2006). This was confirmed in stem cell based engineered myocardium 
(Didié et al., 2013; Jackman et al., 2015; Kensah et al., 2012; Zhang et al., 2013). In addition to 
mechanical stimulation, it appeared that electrical stimulation can advance tissue maturation 







Figure 4: Overview of tissue engineering approaches, cell sources and contractility evaluation. 
Cells from various sources are mixed within hydrogels and cast into molds of several shapes and sizes. Tissue 
construct quality can be further enhanced using mechanical and electrical stimulation. Contractile force is either 
measured in (A, B and C) an organ bath or using (D and E) optical recordings. NRCM: neonatal rat cardiomyocyte; 
NMCM: neonatal mouse cardiomyocyte; hESC: human embryonic stem cells; CM: cardiomyocytes; MSC: 
mesenchymal stem cells. Image adapted from Eschenhagen et al. (2012). 
 
With the exciting progress of stem cell research and advances in tissue engineering approaches, 
active research has recently embraced the concept of the generation of stem-cell based 
organoids directly from undifferentiated pluripotent stem cells supported to self-assemble in a 
three-dimensional culture environment (Yin et al., 2016). A wide variety of organoids has been 
recently developed including liver (Huch et al., 2013; Takebe et al., 2013), kidney (Takasato et 
al., 2014), prostate (Karthaus et al., 2014) and brain (Lancaster et al., 2013). The latter, for 
instance, was generated as droplets of matrigel containing neuroectodermal tissues which further 
differentiated into distinct brain regions such as the dorsal cortex, ventral telencephalon and 
choroid plexus (Lancaster et al., 2013). Yet so far no data have been reported for the 
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development of a macro-tissue with functional properties of bona fide myocardium (i.e.: cardiac 
organoid). The following section introduce the concept of a bioengineered heart muscle (BHM) 






2.4 Bioengineered Heart Muscle: Concept and Preliminary Data 
 
Inspired by embryonic development and advances in tissue engineering, we postulated whether 
hPSCs can be dirrected to differentiate and self-assemble into a BHM. This process would 
eventually require the differentiation of hPSCs not only into cardiomyocytes, but also 
supportive stromal cell populations. Proof-of-concept for directed self-assembly of hPSC into 
BHM was developed prior to the start of the thesis (Hudson et al., in revision). Here it was 
demonstrated that hPSC after mixing with a collagen hydrogel could be subjected to a defined 
serum-free stage specific stimulation protocol to form spontaneously contracting BHMs by day 
13 of culture. The stimuli (growth factors and small molecules) were chosen to manipulate key 
signaling pathways important to recapitulate native heart development. By day 22 of culture, 
these tissues developed networks of elongated and striated cardiomyocytes (Fig. 5A) and 
positive inotropic response to increasing extracellular calcium concentrations (Hudson et al., in 
revision; Fig. 5B). 
 
BHM function was further enhanced with the addition of (1) ascorbic acid 2-phosphate (Asc-
2P), (2) TGFβ-1, (3) adjusting extracellular calcium concentrations from 0.4 mmol/L to 
physiological levels and (4) dynamic mechanical stimulation (Hudson et al., in revision). This 
early data provides proof-of-concept that differentiation of stem cells into cardiomyocytes first 
is not necessary for cardiac tissue engineering and can be avoided if systemic control over the 
assembly and differentiation of hPSCs into cardiac organoids is possible. Yet, this model needed 
further characterization and optimization before it can be introduced as a robust tool for the 






Figure 5: Morphological and functional assessment of BHM at day 22.  
(A) Whole-mount staining for α–actinin (green), actin (red) and DNA (blue) showing muscle bundle formation; 
scale bar: 20 μm. (B) Isometric force measurement of BHM showing a positive inotropic response to increasing 
extracellular calcium under 3 Hz electric stimulation (n= 7). FOC: force of contraction. Images taken from Hudson 
et al. (in revision). 
 
We postulated that modulation of key signaling pathways during early heart development may 
influence BHM development. We sought to target four major pathways that are implicated in 
the early cardiac induction of stem cells including TGFβ/Activin/Nodal, BMP, WNT and FGF. 
From those factors, BMPs appear to be particularly crucial for the induction of cardiac 
mesoderm (Burridge et al., 2011; Hudson et al., 2012; Laflamme et al., 2007; Yang et al., 2008; 







2.5 Bone Morphogenetic Protein Signal Transduction 
 
2.5.1 BMP signaling cascade: ligand and pathway 
 
BMPs were first identified in the formation of bone and cartilage (Wozney et al., 1988). Ligands 
of this family can be further divided based on similarity in amino acid sequence, target genes 
and biological activity. However each ligand targets different genes, BMP2, for example,  
promotes extraembryonic endoderm differentiation, whilst BMP4 evokes differentiation into 
mesoderm in hES cultures (Okita and Yamanaka, 2006). In the absence of BMP, the type-II and 
type-I transmembrane serine/threonine kinase BMP receptors (BMPR-II and BMPR-I 
respectively) appear as preexisting homo and heterodimers on the cell membrane (Fig. 6) 
 
Figure 6: BMP signaling pathway. 
BMP ligands bind to the type-II receptors and induce complex formation with type-I receptors which are 
consequently phosphorylated at their GS domain by the active kinase domain of the type II receptor. R-SMADs 
interact with membrane anchoring proteins (e.g. endofin). The activated BMP type-I receptors then phosphorylate 
R-SMADs, which then formed a complex with Co-SMAD, translocate to the nucleus and regulate gene 
transcription via interacting with DNA binding proteins. BMP: bone morphogenetic protein; GS domain: glycine-
serine amino acid rich domain; SMAD: small body size mothers against decapentaplegic; R-SMAD: receptor-





















Upon ligand binding, BMPR-I recruits BMPR-II inducing receptor oligomerization and 
complex formation. Consequently, the active type-II receptor phosphorylates the glycine-serine 
(GS) amino acid rich domain of BMPR-I at serine and threonine residues (Souchelnytskyi et al., 
2002). Endofin, an endosomal protein, binds to activated type-I receptor at its FYVE anchoring 
domain thus recruiting inactive receptor-regulated small body size mothers against 
decapentaplegic (R-SMADs) at its mad homology (MH) 2 domain to the kinase domain of 
BMPR-I for subsequent phosphorylation at two serine residues (Okita and Yamanaka, 2006). 
Post-activation, R-SMADs undergo conformational changes that disrupt their interaction with 
endofin and cause their dissociation from receptor kinases (Qin et al., 2001) to bind with 
SMAD-4 in a 2:1 ratio at its C-terminus (Kawabata et al., 1998). The SMAD complex then 
translocates to the nucleus, recognizes GC rich sequences (Karaulanov et al., 2004; Truksa et 
al., 2009) via SMAD binding element (Uhlen et al., 2015) on SMAD-4 (Miyazono et al., 2010) 
and interacts with DNA binding proteins at its MH1 domain. DNA binding proteins such as 
p300 and CREB-binding protein (CBP) help in loosening nucleosomal structure and increase 
accessibility to transcriptional factors (Dijke et al., 2006) that are thus recruited by the SMAD 
complex at the MH2 domain. 
 
The transcriptional machinery formed is essential for the regulation of BMP target genes. 
Several studies have revealed that BMP signaling induces the transcription of OASIS, PRx2, 
TIEG, Snail and more importantly inhibitor of differentiation (Id)1-3 proteins during 
mesenchymal osteoblastic differentiation (Hayashi et al., 2008). In most cell types, Id proteins 
are thought to be the primary target of BMP signaling. The aforementioned proteins inhibit 
basic-helix-loop-helix (bHLH) transcription factors that are known to upregulate cell 
differentiation by binding at their HLH dimerization motif (Miyazono and Miyazawa, 2002). 
Other targets of BMP signaling include numerous extracellular and intracellular proteins that 
enhance or inhibit the BMP pathway for example, noggin (Groppe et al., 2002; Sebald et al., 
2004; Yuasa et al., 2005), dorsomorphin (Hao et al., 2008), and BMP-activin membrane-bound 
inhibitor (BAMBI) (Miyazono et al., 2010). Additionally, intracellular proteins like inhibitory-
SMADs (I-SMADs) and SMAD ubiquitin regulatory factor 1 (Smurf1) hinder signal 
transduction via degradation or binding. Conversely, receptor guidance molecules (RGM) 





(Samad et al., 2005) and tribbles-like protein 3 (Trb3) (Chan et al., 2007) function to enhance 
BMP signaling via ligand binding to membrane receptors (i.e.: RGM and dragon) or degradation 
of Smurfs intracellularly (i.e.: Trb3 protein). 
 
The regulation of BMP signaling is complex and depends on many extra- and intracellular 
molecules that can inhibit/enhance the overall mechanism. Its function can additionally be 
affected by alternate signaling pathways such as TGFβ/Activin/Nodal, WNT and FGF. These 
parallel pathways partake in various cardiac developmental decisions.  
 
2.5.2 Role of BMP signaling during cardiogenesis 
 
In 1965, Urist et al. identified BMPs first as molecules that help in the induction of 
endochondral osteogenesis in vivo (Urist, 1965). However, knock-out mouse models revealed 
that the role of individual BMPs in development is not restricted to bone and cartilage, but 
central for embryogenesis as a whole and the formation of many organ systems such as skeletal, 
urinary, neurological and most importantly cardiovascular system. 
 
BMPs play a crucial role during embryonic gastrulation and specifically also for cardiac 
development. Accordingly, a knock-out of BMP2/4 is embryonically lethal and BMP1/7/11 
knockout mice die shortly after birth (Wang et al., 2014). Deficiency of BMP2 alone led to 
cardiac malformations particularly in the development of heart valves and septa (Rivera-
Feliciano and Tabin, 2006). This similar phenotype was also observed in BMP6 and 7 double 
knock outs (Kim et al., 2001). Other knockout studies revealed a role for BMP10 in 
cardiomyocyte proliferation (Chen et al., 2004). Moreover, the lack of both extracellular (i.e.: 
receptors) and intracellular (i.e.: R/Co/I-SMADs) regulators in mice results in embryonic 
lethality (Wang et al., 2014). SMAD1 mutants have defects in extraembryonic structures and 
formation of germ cells (Mishina et al., 1995; Tremblay et al., 2001). SMAD5 knockouts exhibit 
defects in left-right asymmetry (Chang et al., 2000). 
 
BMP4 and its type-I receptor deficient mice lack the ability of mesodermal differentiation 





three germ layers, BMP4 is released from the extra-embryonic ectoderm to the anterior medial 
mesoderm with cardiogenic properties (Arnold and Robertson, 2009; Burridge et al., 2012; Tam 
and Loebel, 2007). This process occurs in a narrow time window that permits cells to transiently 
express the mesodermal marker Brachyury T (Zhu et al., 2013). Further long term exposure to 





Figure 7: Signaling pathways and gene regulators governing cardiomyogenesis. 
Wnt: Wingless signaling; BMP: bone morphogenetic protein signaling; FGF: fibroblast growth factor signaling; 
SHH: sonic hedgehog signaling; GSK3β: glycogen synthase kinase 3; TGFβ-1: transforming growth factor β-1; 
p38MAPK: p38 mitogen-activated protein kinases; PSCs: pluripotent stem cells. Image adapted from (Verma et al., 
2013). 
 
Stimulation of pre-cardiac mesoderm derived cell populations from hPSCs with BMP4 along 
with Wnt signaling inhibition induces cardiomyocyte specification. However, BMP4 activation 
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alone causes the formation of epicardial cells expressing WT1 and TBX18 (Witty et al., 2014). 
Another role of BMP4 in cardiac lineage specification was demonstrated by Cagavi et al. (2014) 
where cardiac differentiation was enhanced upon the stimulation of cardiac progenitor cells 
expressing ISL1 with BMP4 via the activation of TBX5 and TBX20 normally expressed in the 
first and second heart fields (Cagavi et al., 2014). Additionally, and using mice knockouts it has 
been shown that following cardiac crescent formation and heart patterning, BMP signaling has a 
role in atrioventricular (Jiao et al., 2003) and outflow tract (Liu et al., 2004) septation. In zebra 
fish, BMP4 has a crucial role in directing cardiac asymmetry (Lenhart et al., 2013). 
 
The recapitulation of cardiac differentiation in vitro at stage-specific windows has been made 
possible due to the extensive studies of the BMP pathway in animal models (Fig. 7). While the 
advancing differentiation methodologies are becoming highly defined and serum-free as 
discussed in section 1.2, challenges involving line-to-line variability between cells still remain, 
which ultimately affect the response to endogenous factors thus reducing the reproducibility and 
efficiency of cardiac differentiation. Several groups have demonstrated that the vast 
inconsistency in differentiation among pluripotent stem cell lines is likely due to the differences 
in initial state of pluripotency (Burridge et al., 2011; Hudson et al., 2012; Mummery et al., 
2012) as well as genetic and epigenetic differences between hES cell lines (Adewumi O, 2007; 
Allegrucci and Young, 2007; Skottman et al., 2005). In addition, the protein factors used as 
culture medium supplement for directed differentiation can exhibit considerable batch-to-batch 
differences in biological activity. This technical challenge may be overcome by replacement of 
biological factors with small molecules that target the typically growth factor activated key 
pathways of cardiac differentiation. 
 
Advantages of well characterized small molecules over protein-based regulators include their 
easy membrane diffusion, instant activation/inhibition of selective targets, reversible mode of 
action (Willems et al., 2009) and low cost in comparison to recombinant proteins (Wang et al., 
2011). Furthermore, their potency, selectivity and solubility can be adapted as needed by 
chemical modulation (Willems et al., 2011). The synthesis and characterization of these discrete 
molecules remain the hope for generating a universal differentiation protocol that will help 






2.5.3 Chalcones: potential candidate for BMP4 replacement  
 
In a recent screen for small molecule activators of BMP signaling using luciferase assay under 
the Id1 promoter, four compounds out of 5600 molecules tested from different libraries 
belonging to the family of flavonoids induced luciferase activity greater than 50% relative to 
BMP4 (Vrijens et al., 2013). Two of these compounds were chalcones (isoliquiritigenin and 4’-
hydroxychalcone, Fig. 8A) and the other two were flavones (apigenin and diosmetin). Only the 
former compounds activated BMP signaling via the phosphorylation of SMAD 1/5 as well as 
the expression of Id1 target gene of BMP pathway in a concentration dependent manner (Fig. 
8B). 
 
Figure 8: Small molecule activators of BMP signaling.  
(A) Chemical structure of isoliquiritigenin (left) and 4’-hydroxychalcone (right). (B) Immunoblotting showing the 
activation of BMP signaling using antibodies for phosphorylated Smad 1/5, total Smad 1/5, Id1 and Id2 upon 
treating cells with increasing concentrations of isoliquiritigenin (left) and 4’-hydroxychalcone (right). Actin was 
used as a loading control. Id: inhibitor of differentiation; BMP4: bone morphogenetic protein 4; SMAD1/5: Small 
body size Mothers Against Decapentaplegic 1/5; pSMAD1/5: phosphorylated SMAD1/5. Image taken from Vrijens 
et al. (2013). 
 
Chalcones or (E)-1,3-diphenyl-2-propen-1-ones are open chain flavonoids ubiquitously present 








chalcones are at a continuously growing interest for medicinal chemists. The α,β-unsaturated 
ketone moiety allows the presence of cis and trans isomers of which the latter is more 
thermodynamically stable. It is also regarded as the main pharmacophore since studies have 
shown that bioactivity of chalcones is diminished with the full or partial loss of this moiety 
(Batovska and Todorova, 2010). However, it is also owing to the diverse phenyl substituents 
(such as hydroxyl, methoxy, alkyl, halogen, nitro-, amino-, etc.) that chalcones demonstrated a 
wide variety of bioactivities including anti-oxidant, anti-microbial, anti-cancer and anti-
inflammatory activities (Fig. 9). 
 
In many cases, the same compound may have multiple biological properties. Isoliquiritigenin 
has recently shown to activate BMP signaling, but has also been used as an inhibitor of voltage-
operated K
+
 channels (Kv2.1) in rat cardiac myoblasts. This chalcone-induced positive inotropic 
response operated via increasing L-type calcium currents (Noguchi et al., 2008). 
Isoliquiritigenin can also inhibit the effects of cocaine by acting on the GABAB receptor (Jang et 
al., 2008) and exhibit anti-inflammatory activities (Batovska and Todorova, 2010; Zhou and 
Xing, 2015). The potential target profile of these chemotypes can present an obstacle to future 
clinical trials. However, their bioactivity in targeting signaling pathways (e.g. BMP) has yet to 






Figure 9: Backbone of the chalcone family and examples of biological activities.  
Image adapted from Batavska and Todorova (2010). 
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2.6 Thesis Objectives and Hypotheses 
Building on the proof-of-concept for the directed self-organization of hPSC into cardiac 
organoids, introduced as bioengineered heart muscle (BHM) by our lab (Hudson et al., in 
revision), the objectives of this thesis entailed: (1: Chapter 3.1) a thorough characterization of 
the BHM model at the morphological, functional, and molecular level; (2: Chapter 3.2) the 
assessment of conditions that would allow for enhanced tissue maturation; (3: Chapter 3.3) 
identification of small molecule BMP4 mimics as a first step towards the development of 
protein-free directed differentiation and self-assembly of hPSCs into cardiac organoids. 
Accordingly, the following specific hypotheses were investigated: 
 
1. BHM can be used to simulate human heart development. 
2. Further functional maturation of BHM can be induced in long-term cultures. 
3. Chalcones can be used to induce mesoderm formation in hPSCs. 
 











BHM can be used to simulate human 
heart development. 
Further functional maturation of BHM 
can be induced in long-term cultures. 
Chalcones can be used to induce 









3 Materials and Methods 
 
3.1 Cell Culture 
 
The import and experimentation with human embryonic stem cells (hESCs) was approved by 
the Robert-Koch-Institute (Az 1710-79-1-4-16-E1/2). 
 
3.1.1 Human feeder cell preparation 
 
Human foreskin fibroblasts (HFF) were cultured in fibroblast medium (Dulbecco’s modified 
eagle medium (DMEM; Invitrogen) containing 20% of fetal bovine serum (FBS; PAA) and 100 
IU/mL penicillin and 100 μg/mL streptomycin ([P/S]; Invitrogen) supplemented with 20 ng/mL 
of fibroblast growth factor-2 (FGF-2; Miltenyi Biotech). Irradiated HFFs (IR-HFFs) were 
obtained by exposing HFFs to 30 Gray γ-irradiation (STS Biobeam 8000, Germany) and 






3.1.2 Human embryonic stem cell culture 
 
hESC cultures of HES2 cell line (originally obtained from ES-International, Singapore) were 
maintained on IR-HFF layers in HES medium (Dulbecco’s modified eagle medium (DMEM; 
Invitrogen) containing 20% of Knock-out serum replacement (KOSR; Invitrogen) and FGF-2 
was added at 10 ng/mL. Passaging with TrypLE Express (3 mL/flask; Invitrogen) was 
performed at day 7 followed by splitting over several passages onto IR-HFFs to obtain single 
cell suspensions ready to be transferred to feeder-free conditions. This involved cells passaged 
and plated at 25.000 cells/cm
2
 in maintenance medium (HES and IR-HFF conditioned medium 
[1:1] supplemented with 20 ng/ml FGF-2) for three days on plates precoated for 60-90 minutes 
with Matrigel (BD Bioscience, 1:30 in phosphate buffered saline (PBS). The aforementioned 
step was done prior to initiation of differentiation (day-4). IR-HFF cultures (2.000 cells/cm
2
) 










3.2  2D Cardiac Differentiation 
 
3.2.1 Differentiation medium 
 
hESCs were cultured in basal medium: Rosewell Park Memorial Institute (RPMI 1640) 
supplemented with P/S, 1 mmol/L sodium pyruvate and 2% B27 serum replacement supplement 
with insulin (all Gibco) in the presence of L-ascorbic acid 2 phosphate sesquimagnesium salt 
hydrate (ASC; Sigma; 200 µmol/L). Factors were added to the medium as indicated in (Fig. 11). 
 
 
Figure 11: Outline of the cardiac differentiation of HES2 cells in monolayer cultures.  
HES2: human embryonic stem cell line 2, A: activin-A, B: bone morphogenetic protein 4, C: CHIR99021, F: 
fibroblast growth factor-2, IWP4: inhibitor of Wnt production 4, ASC: L-ascorbic acid, RPMI: Rosewell Park 
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3.2.2 Monolayer differentiation 
 




 coated multi-well 
plates in maintenance medium. 24 hours later, cells were washed with basal medium first (0.5 
mL/well in a 24-well plate) before the start of the mesoderm induction phase (3 days); following 
growth factors were added to the basal medium for mesoderm induction: CHIR99021 
(Stemgent; 1 µmol/L), FGF-2 (5 ng/mL), BMP4 (R&D systems; 5 ng/mL), Activin-A (R&D 
systems; 9 ng/mL). Culture medium was exchanged daily until day 3 (3 medium changes). 
Subesquently, cardiac specification was induced for 10 days with the addition of an inhibitor of 
Wnt production (IWP4; Stemgent; 5 µmol/L) to the basal medium, which was exchanged every 
2-3 days until day 13 (4 medium changes). Thereafter, cardiomyocytes were maintained in basal 
medium with medium exchanges every 2 days (4 medium changes). Beating was observed 
starting day 13 and the cells were harvested on day 22. 
 
3.2.3 Dissociation of differentiated hESC 
 
Cells were rinsed with PBS first, followed by incubation for 15 minutes in Accutase solution 
(Millipore) supplemented with 0.025% Trypsin (2.5%; Gibco) and 2% DNase I (1 mg/mL stock 
solution; Calbiochem) at room temperature (0.5 mL/well). The cells were then collected in a 
tube, rinsed with 5% FBS in PBS and pelleted at 300 x g for 4 minutes. Following aspiration of 
the supernatant, the dissociated cells were then fixed in ethanol (70%) for flow cytometry.  
 
3.3 Bioengineered Heart Muscle Generation 
 
3.3.1 Preparation of casting molds and dynamic stretchers 
 
For the generation of BHMs, circular molds of inner/outer diameter 4/10 mm were fabricated 
using poly-dimethylsiloxane (PDMS; Sylgard, Dow Corning) and allowed to harden overnight 
at 55°C (Fig. 12A). The detailed protocol for the preparation of the casting molds has been 
described before (Soong et al., 2012; Tiburcy et al., 2014). Similarly, silicone based flexible 





and used to facilitate auxotonic contractions of BHMs (Fig. 12B). Both the assembled casting 
molds and the flexible stretchers can be autoclaved and reused. 
 
 
Figure 12: Casting mold and silicone poles for BHM generation and loading.  
(A) Glass culture dish filled with transparent silicone and 4 circular recesses with central spacers. Each circular 
recesses (diameter= 10 mm) has a central silicone core (diameter= 2 mm) which has a thin silicone tubing (length= 
10 mm) placed over it to provide an inner spacer during BHM generation. (B) Dynamic silicone poles (length= 12 
mm, thickness= 1.5 mm, inner/outer distance= 6/7.5 mm). Images adapted from Tiburcy et al. (2014). 
 
 
3.3.2 Bioengineered heart muscle assembly and differentiation 
 
BHMs were prepared from HES2 cells maintained for 3 days in feeder-free conditions (see 
section 2.1.2). At day -1 cells were dissociated into single cells using TrypLE and 5x10
5
 HES2 
cells suspended in maintenance medium were mixed with the BHM reconstitution mixture 
composed of 1:1 v/v mix of acid solubilized bovine collagen I (LLC collagen solutions) and 2X 
DMEM (Gibco) neutralized by titration with 0.1 mol/L sodium hydroxide. The final collagen I 
concentration was 1 mg/mL. 170 µl of the BHM reconstitution mixture was cast into the molds 
and allowed to consolidate for one hour at 37°C after which maintenance medium (1.25 
A
B 
(i) (ii) (iii) 





mL/BHM) was added (Fig. 13). 24 hours later, BHMs were first rinsed with RPMI medium then 
induced to differentiate to cardiac lineage with temporal addition of growth factors and small 
molecules as outlined in the schematic below. At day 13, BHMs were transferred on to dynamic 
stretchers and cultured for 9 days in basal medium with adjusted calcium concentration from 0.4 
mmol/L to physiological concentration of 1.2 mmol/L. TGFβ-1 (1 ng/mL) or other factors were 
screened for further BHM maturation. Analysis and characterization of BHMs were performed 
at day 22 unless indicated otherwise. 
 
 
Figure 13: Outline of HES2-BHM generation and differentiation.  
HES2 cells were mixed with collagen type I and cast (i) into empty circular molds. (ii) After 24 hours the tissue 
constructs condensed and exposed to sequential addition of growth factors and small molecules to enhance 
mesoderm induction, cardiac specification and cardiac maturation. BHMs are subjected to (iii) mechanical loading 
at day 13 and cultured further till day 22. HES2: human embryonic stem cell line 2; A: activin-A; B: bone 
morphogenetic protein 4; C: CHIR99021; F: fibroblast growth factor-2; IWP4: inhibitor of Wnt production 4; 
TGFβ-1: transforming growth factor β-1; RPMI: Rosewell Park Memorial Institute basal medium; B27: defined 
culture medium supplement; ASC: ascorbic acid; d: days. Image adapted from Hudson et al. in revision. 
 
3.3.3 Bioengineered heart muscle dissociation 
 
Collagenase (0.2%; Sigma) prepared in PBS (with calcium/magnesium) with 20% fetal bovine 
serum (FBS; Gibco) was added (1 mL/BHM) for 60-90 minutes at 37°C after which the 
supernatant was collected in a falcon tube (15 mL) and the remaining large pieces from each 
digested BHM were resuspended in 1 mL of Accutase solution (Millipore) supplemented with 
0.025% Trypsin (2.5%; Gibco) and 2% DNase I (1 mg/mL stock solution; Calbiochem) for 30 





and the whole mixture was pipetted and transferred to the same falcon tube. Single cells 
obtained from the dissociated BHMs were then either fixed in ethanol (70%) for staining of 





3.4.1 Isometric force measurement 
 
BHMs were suspended in organ baths at 37°C in gassed (5% CO2 / 95% O2) Tyrode’s solution 
(mmol/L: NaCl 126.7, KCl 5.4, CaCl2 0.2, MgCl2 1.05, NaHCO3 22, NaH2PO4 0.42, glucose 
5.6, ascorbic acid 0.56; pH 7.4). Calcium concentration was adjusted using CaCl2 solution (0.2 
mol/L) diluted from stock solution (2.25 mol/L). After calibration and reaching equilibrium, 
BHMs were stimulated with electric field pulses (2 Hz, 5 ms, 200 mA) at 2 mmol/L calcium and 
stretched stepwise by 125 µm until the twitch tension reached a maximum value according to 
the Frank-Starling mechanism (this encompassed typically 4 x 125 µm stretches). All 
subsequent analyses were performed at Lmax, defined as the tissue length with maximal detected 
force of contraction (twitch amplitude). The maximal inotropic capacity was assessed by 
investigating the inotropic response to cumulatively increasing calcium concentrations (0.2-4 
mmol/L unless indicated otherwise). Response to β-adrenergic stimulation using Isoprenaline (1 
μmol/L) was investigated at EC50 calcium concentration. 
 
3.4.2 Action potential recordings 
 
With the help of Dr. Mei-Ling Liao (Institute of Pharmacology and Toxicology), impaling 
electrode measurements on the BHMs were performed. BHMs were pinned down in a 
customized chamber and perfused with Tyrode’s solution (1 mL/minute, 35-37°C; mmol/L: 
NaCl 150, KCl 5.4, MgCl2 2, CaCl2 1.8, HEPES 10, glucose 10; pH 7.4; 100% O2). 
Microelectrodes with 30-50 MΩ tip resistance were filled with 2 mol/L KCl and used to impale 
cardiomyocytes in BHM. Signals were acquired (LIH 8+8 Interface, HEKA) and amplified 





Cardiomyocyte action potentials can be grossly subdivided into action potentials typically 
observed in ventricular and pacemaker myocytes (Fig. 14A). The differences in action potential 
kinetics are determined by the expression and phase specific activation of specific ion channels 








Figure 14: Action potential traces and membrance currents from ventricular and pacemaker cells. 








3.4.3 Flow cytometry 
 
Cells dissociated from 2D/3D differentiation procedures and fixed with ethanol or 4% 
formaldehyde solution were resuspended in blocking buffer (PBS supplemented with 5% FBS, 
1% bovine serum albumin [BSA], 0.5 % Triton X-100 and sodium azide; used for internal 
markers) or 5% FBS in PBS (for cell surface markers) and permeabilized for 10 minutes at 4°C 
then filtered using a cell strainer (40 μm). Samples were incubated for 45 minutes at 4°C with 
primary antibodies (Table 4, Appendix), followed by two washing steps with blocking buffer 
prior to incubation with secondary antibodies in blocking buffer (Table 4, Appendix) and 
Hoechst 33342 for 30 minutes at 4°C. Samples were then again washed with blocking buffer 
and resuspended in PBS for analysis with a BD LSRII flow cytometer (BS Biosystems). Viable 
cells were first gated based on Hoechst 33342 staining. The gating strategy for α-actinin positive 
cells is shown in (Fig. 15); single cells were gated based on forward scatter signal, IgG controls 
were used to determine non-specific staining. BD FACSDiva Software (BD Biosciences) or 
Cyflogic Software were used for analysis. 
 
Figure 15: Gating strategy for α–actinin
+
 cardiomyocytes.  
Viable cells in G1 + G2 were selected based on Hoechst3342 intensity. Doublets were excluded based on forward 
scatter width (FSC-W). Cardiomyocytes were distinguished based on actinin positivity. IgG1 was used as an 
isotype control for non-specific staining.  
 








3.4.4 Quantification of cardiomyocyte size using flow cytometry 
 
Cardiomyocyte size in the different experimental conditions was assessed using the median side 
scatter intensity (SSC) in the gated α-actinin positive cell population. 
 
3.4.5 Whole mount staining and confocal imaging 
 
To visualize BHM morphology and cellular composition, whole mount staining and imaging 
were performed. Prior to immunostaining, BHMs were fixed with formaldehyde solution (4%; 
overnight, 4°C). Samples were then permeabilized with 0.005% Triton X-100 for one hour at 
room temperature followed by three washing steps with PBS. Samples were blocked with 
Rotiblock
TM
 (Roth) overnight at 4°C and subsequently incubated at 4°C with primary antibodies 
(Table 4, Appendix) in PBS with constant rotation for two nights. Prior to incubation with 
secondary antibodies for two nights at 4°C in PBS, samples were washed 3 times in PBS. 
Subsequent washing with PBS proceeded mounting the BHMs with fluoromont (Southern 
Biotech) on microscope slides covered with a coverslip to compress BHM equally. Fluorescence 
was then visualized with a Zeiss 710 NLO confocal microscope. 
 
3.4.6 Transmission electron microscopy 
 
TEM measurements were performed in collaboration with Wiebke Moebius at the Max-Planck-
Institute for Experimental Medicine. The detailed procedure has been described before 
(Zimmermann et al., 2002). In short, BHM sections (1x2 mm) were fixed in 2.5% 
glutaraldehyde in PBS containing 1 mmol/L CaCl2 and 30 mmol/L 2,3-Butanedione-2-
monoxime (BDM) overnight at 4°C. After an overnight wash in 0.1 mol/L phosphate buffer pH 
7.3 samples were post-fixed in 2% OsO4 (Science Services) and 3% potassium ferricyanide 
(1:1) in 0.1 mol/L phosphate buffer pH 7.3 for 4 hours at 4°C and embedded in EPON (SERVA 
Electrophoresis GmbH) after dehydration with ethanol and propylenoxide. Ultrathin sections of 
50 nm thickness were prepared with a Ultracut S ultramicrotome (Leica), stained with an 





taken with a LEO EM912 omega electron microscope (Zeiss) using an on-axis 2k CCD camera 
(TRS, Moorenweis, Germany). 
 
3.4.7 Gene expression analysis 
 
3.4.7.1 RNA preparation 
 
Total RNA was isolated from cells and BHM using the Trizol
TM
 (Invitrogen) standard extraction 
protocol. Cells/BHMs were first washed in PBS. Subsequently, 1 mL of Trizol reagent was 
added for 5 minutes at room temperature. Cells were then scratched off the culture plates using 
cell scrapers and the supernatant was collected. BHMs were lysed using Tissue Lyser II 
(Qiagen) at 25 Hz for 5 minutes at 4°C in the presence of 7 mm stainless steel beads (Qiagen). 
Chloroform (200 μL/sample) was then added, followed by thorough vortexing. After incubation 
for 10 minutes at room temperature, phase-separation was facilitated by centrifuging at 12.000 x 
g and 4°C for 10 minutes. The upper aqueous phase was transferred to RNase-free reaction tube 
(2 mL; Eppendorf). The RNA was pelleted by incubation in isopropanol (500 μL/sample) for 10 
minutes at room temperature and centrifuging at 12,000 x g (at 4°C for 10 minutes). Following 
removal of the supernatant, the RNA pellet was washed with 75 % ethanol (1 mL/sample) and 
the tubes were spun at 12,000 x g (at 4°C for 5 minutes). The RNA pellet was air-dried for 10 
minutes and resuspended in DEPC water (25 μL/sample, Sigma). RNA concentration was 
quantified using the Nanodrop spectrophotometer (Thermo Scientific) and samples were stored 
at -80°C. RNA samples had an average of 260/280 ratio of 1.8. 
 
3.4.7.2 cDNA synthesis 
 
To remove potential genomic DNA contamination, RNA samples were treated with DNase I 
(Roche) as follows; 0.2 μL of DNase I (10 U/μL) was added to 1 μg of RNA mixed with 1 μL of 
DNase incubation buffer. The mix was then incubated for 20 minutes at 37°C. To inactivate the 
enzyme, 1 μL of EDTA (0.2 mmol/L, pH 8) was added to the mix which was incubated further 






High Capacity cDNA Reverse Transcription Kit (Applied Biosystems) was used for reverse 
transcription according to manufacturer’s instructions. For one reverse transcription (RT) 
reaction, 25X dNTPs (0.8 μL) were mixed with 10X RT random primers (2 μL) in 10X RT 
buffer (2 μL) and DEPC treated water (2.2 μL). RNase inhibitor (1 μL) was added to the master 
mix from which 8 μL was transferred to each DNase treated samples. To control for unwanted 
genomic DNA amplification, a negative control from each condition was processed in which 
RNase free water (1 μL) replaced the MultiScribe
TM
 Reverse Transcriptase. The samples were 
then transferred to the T gradient thermocycler (Biometra) and the following program was run 
(25°C for 10 minutes, 37°C for 120 minutes, 85°C for 5 minutes then paused at 4°C). After 
cDNA synthesis, the samples were stored at -20°C to be used later for semiquantitative or 
quantitative polymerase chain reaction (PCR). 
 
3.4.7.3 Quantitative RT-PCR (qPCR) 
 
qPCR was done using Fast SYBR Green Master Mix (PCR Biosystems) on a 384-well format 
AB7900 HT Fast Real-Time PCR system (Applied Biosystems). For product specificity no 
template and no reverse transcriptase served as control. Expression profile was analyzed using 




 molecules/μL) by 
SDS2.4 software. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as a house 
keeping gene for normalization. Primer details are listed in the Appendix. 
 
3.4.8 RNA sequencing and bioinformatics analyses 
 
RNA sequencing was performed at the Microarray and Deep-Sequencing Facility of the 
University Medical Center Goettingen (head: Dr. Gabriela Salinas-Reisters). As described 
above, total RNA was isolated and integrity was assessed with the Agilent Bioanalyzer 2100. 
Only samples exhibiting a RNA integrity number (RIN) of > 7 were subjected to RNA 
sequencing. Total RNA (n=4 from 3 independent experimental series for each investigated time-
point) was subjected to library preparation (TruSeq Stranded Total RNA Sample Prep Kit from 
Illumina) and RNA-sequencing on an Illumina HighSeq-2000 platform (SR 50 bp; >25 Mio 





Regeneration in Goethe-University Frankfurt (Dr. Shizuka Uchida), the raw data (FASTQ) were 
mapped to GRCh38/hg38 using TopHat2 (Kim et al., 2013) and analyzed by Cufflinks (Trapnell 
et al., 2012) to calculate Fragments Per Kilobase of Exon per Million Fragments (FPKM) 
values. Data with the biotype “protein_coding” and FPKM >1 were considered for further 
analysis. Self-organizing tree algorithm (SOTA) (Dopazo and Carazo, 1997; Herrero et al., 
2001) was assessed using MultiExperiment Viewer (MeV) (Saeed et al., 2003). Gene ontology 
(GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis was 
performed through DAVID (Huang da et al., 2009). All RNA-seq data sets have been deposited 
in the Gene Expression Omnibus. 
 
3.4.9 Western blot 
 
3.4.9.1 Protein extraction from monolayer cells 
 
To obtain cell lysates from 2D cultures, HES2 cells were first rinsed with ice-cold PBS then 
scratched off from the culture dish using a cell scraper, collected in a 1.5 mL reaction tube 
(Eppendorf) and pelleted at 12,000 x g for 4 minutes. Next, 200 μL of CytoBuster
TM
 lysis buffer 
(Novagen) supplemented with phosphatase and protease inhibitors was added to the cell pellet 
and incubated at room temperature for 15 minutes while mixing thoroughly to homogenize. The 
supernatant was subsequently transferred to new polypropylene collection tubes (Eppendorf). 
The cell debris in samples from monolayer cultures was then pelleted at 12,000 x g for 20 
minutes at 4°C. The resulting supernatant was then referred to as protein lysate and transferred 
to a new collection tube (Eppendorf) and stored at -20°C until further use. 
 
3.4.9.2 Western blotting 
 
Prior to Western Blotting, protein concentration from each sample was quantified using 
Bradford assay with BSA (Sigma-Aldrich) as a standard. Sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE) was used to separate proteins from a protein 
lysate according to their molecular mass. Negatively charged SDS binds to proteins and leads to 





Appendix. Briefly, 15 μg of protein lysates were loaded on a 6% collecting gel (Appendix) after 
mixing for 5 minutes at 95°C in 4 × Laemmli buffer. Proteins were then resolved on a 10% 
separating gel (Appendix). Protein collection was done at 70 V for 20 minutes and seperated at 
140 V for 50 minutes. Proteins were transferred from the PAGE to polyvinylidene fluoride 
(PVDF) membrane in a vertical electric field at 140 mA for one hour. Next, the membrane was 
blocked in 5% BSA in TBST buffer (Tris-HCl [20 mmol/L, pH 7.6] containing 0.1% Tween-20 
[Tween
®
 20, Sigma-Aldrich] and NaCl [165 mmol/L, Roth]) for one hour at room temperature 
then incubated overnight at 4°C in primary antibody diluted in blocking buffer (5% BSA in 1 x 
TBST). Following three washing steps with TBST, the membrane was incubated with secondary 
antibody (also diluted in blocking buffer) for one hour at room temperature. The list of primary 
and secondary antibodies used in this study and their respective dilution factor are listed in the 
Appendix. The membrane was again washed three times with TBST prior to incubation with 
horseradish peroxidase substrate (SuperSignal West Femto kit, Pearce, Thermo Scientific) for 5 
minutes. Protein bands were detected using VersaDoc
TM
 XR Imaging System and analyzed 
using Image Lab (BioRad). 
 
3.4.10 Statistical analyses 
 
All data were analyzed using GraphPad Prism software (GraphPad Software Inc) and displayed 
as mean ±standard error of the mean. n indicates the number of samples whether monolayer or 
BHM analyzed. Statistical analyses used were t-test, one-way or two-way ANOVA unless stated 
otherwise. Results showing P < 0.05 were considered significant. 
 






4 Results  
 
The results of this thesis are divided into three main chapters as indicated in the Introduction. 
 
4.1 Characterization of a Bioengineered Heart Muscle 
 
4.1.1 Directed self-assembly of bioengineered heart muscle 
 
hPSC can differentiate and self-assemble into BHM in a collagen hydrogel when subjected to 
sequential addition of growth factors and small molecules as described in 2.3.2. BHM 
development is characterized by (1) mesoderm induction for 3 days in the presence of a small 
molecule Wnt signaling activator CHIR99021 (1 μmol/L), FGF-2 (5 ng/mL), Activin-A (9 
ng/mL) and BMP4 (5 ng/mL), (2) cardiac specification for 10 days in the presence of the Wnt 
signaling inhibitor IWP4 (5 μmol/L) and (3) cardiac maturation from culture day 13 on under 
mechanical stimulation, TGFβ-1 (1 ng/mL) and increase in extracellular calcium from 0.4 
mmol/L to physiological concentrations of 1.2 mmol/L. Cardiac maturation was maintained for 
up to 50 days in this study. BHM developed under these conditions served as controls unless 
indicated otherwise. The notable difference from other directed differentiation protocols is the 
parallel development of cardiomyocytes and stroma cells in a three dimensional growth context 
from the same starting cell source, namely human pluripotent stem cells. 
 
In the following sections molecular, functional and morphological properties of the BHM model 
are presented along with proof-of-concept that this model can be used for applications in 
simulations of cardiac development, disease modeling and drug screening. 
 
4.1.2 Gene expression profiling of developing bioengineered heart muscle 
 
BHMs at different time points of development were subjected to RNA extraction. RNA was 
then subjected to sequencing followed by a bioinformatics analysis of the resulting data. RNA 





induction with the reduction of the pluripotency markers such as OCT4 and a transient induction 
of mesodermal markers (i.e. MESP1 and MIXL1) peaking at day 3. Cardiac specification was 
characterized by the expression of cardiac progenitor markers including NKX2-5 and ISL1 (peak 
at day 8) with concurrent increase in the expression of TBX5. The cardiac maturation phase was 
characterized by the expression of definitive cardiac markers MYH6, MYH7 and MYL2 (Fig. 16). 
The increase of the MYH7/MYH6 ratio, although still not at adult heart levels (28±5 for adult 
heart [kindly provided by Dr. Karl Toicher] vs. 0.4±0.2 for BHM at day 22; n=4/group), may be 
interpreted as a molecular sign of BHM maturation. 
 
Figure 16: Molecular profiles during BHM development.  
(A) Outline of the BHM differentiation protocol as developed by Hudson et al. (in revision). (B) Analysis of RNA 
sequencing data for pluripotency (OCT4) and early mesoderm (MIXL1, MESP1), cardiac progenitor (NKX2-5, ISL1, 
TBX5) and cardiomyocyte markers (MYH6, MYH7, MYL2). n=4 BHMs/time point from three independent 
experiments. * P < 0.05 vs. -1d by ANOVA with Dunnett’s multiple comparison post-hoc test. BHM: 
bioengineered heart muscle; OCT4: octamer-binding transcription factor 4; MIXL1: mix paired-like homeobox 1; 
MESP1: mesoderm posterior basic helix-loop-helix transcription factor 1; NKX2-5: NK2 transcription factor 
related locus 5; ISL1: islet 1; TBX5: T-box transcription factor 5; MYH6: myosin heavy chain 6; MYH7: myosin 
heavy chain 7; MYL2: myosin light chain 2; d: days; FPKM: fragments per kilobase of exon per million fragments. 
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4.1.3 Cell composition of bioengineered heart muscle 
 
BHMs were subjected to enzymatic digestion at different time points of differentiation to 
determine the total cell count. The analyses showed a gradual increase in cell number reaching 
more than three times of the input cell number by day 13 (2.3±0.2 x10
6
 cells at day 13 vs. 0.5 
x10
6
 at day -1; n=4; p<0.05; Fig. 17A), after which this number dropped again markedly to 
0.8±0.1 x10
6
 cells by culture day 22 (Fig. 17A). Flow cytometry for different markers at culture 
day 22 revealed that BHMs were composed mainly of 43±2% cardiomyocytes marked by α-
actinin and 29±2% stroma cells marked by CD90 with minimal presence of hematopoietic cells 
(marked by CD117 and CD45) and endothelial cells (marked by CD31) (Fig. 17B). Further 
analysis of RNA-sequencing data demonstrated transcriptional activity suggesting epicardial 
(WT1 and ALDH1A2) and endocardial (CD31 and VE-Cadherin) developmental processes 
starting at the cardiac specification phase and continuing until day 22 (Fig. 17C and E). This 
was also observed upon staining for the epicardial marker WT1 at both culture days 13 and 22 







Figure 17: Changes of cell number and composition of BHM. 
(A) Total cell count per BHM during differentiation (n=4 BHMs/time point). * P < 0.05 vs. -1d by ANOVA with 
Dunnett’s multiple comparison post-hoc test. (B) Flow cytometry analysis of the BHM cell composition at culture 
day 22. (C) RNA sequencing data analyses for canonical epicardial markers (WT1, ALDH1A2); n=4 BHMs/time 
point from three independent experiments. * P < 0.05 vs. -1d by ANOVA with Dunnett’s multiple comparison 
post-hoc test (D) Whole-mount staining for WT1 (green) and DNA (blue) marking putative epicardial cells in 
BHMs isolated at day 13 and day 22; Overview of BHM (left panel; scale bar: 2 mm) and magnified region (right 
panel; scale bar: 20 μm) are displayed. (E) RNA sequencing data showing endocardial-like activity (CD31 and VE-
Cadherin gene expression) in BHMs (n=4 BHMs/time point from three independent experiments). * P < 0.05 vs. -
1d by ANOVA with Dunnett’s multiple comparison post-hoc test. BHM: bioengineered heart muscle; CD90: thy-1 
cell surface antigen; CD117: kit proto-oncogene receptor tyrosine kinase; CD45: leukocyte common antigen; 
CD31: platelet/endothelial cell adhesion molecule; WT1: Wilms tumor 1; ALDH1A2: aldehyde dehydrogenase 1 
family member A2; VE-Cadherin: vascular endothelin-cadherin; DNA: deoxyribonucleic acid; FPKM: fragments 
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4.1.4 Functional properties of bioengineered heart muscle 
 
4.1.4.1 Isometric force measurement 
 
Spontaneous beating of BHMs was detected by culture day 13 prior to mechanical stretching 
and continued so until functional analysis at day 22. Isometric force measurements revealed 
positive inotropic response to increasing extracellular calcium and β–adrenergic stimulation 
with isoprenaline (1 μmol/L) as shown in Fig. 18 A and B, respectively. The apparent half 
maximal effective concentration (EC50) of calcium was calculated to be 0.4±0.1 mmol/L (n=20). 
 
Figure 18: Functional assessment of culture day 22 BHM. 
Isometric force measurements showing positive inotropic response of BHMs to (A) increasing extracellular calcium 
with an EC50= 0.4±0.1 mmol/L (striped line) and (B) β–adrenergic stimulation under isoprenaline (1 μmol/L) at 0.6 
mmol/L calcium is represented in the bar graph (n=20 BHMs). FOC: force of contraction; EC50: effective 
concentration at half maximal effect; Iso: isoprenaline. 
 
4.1.4.2 Electrophysiological characterization 
 
In order to see which of the cardiac specific cell types is predominant in the BHM, action 
potentials were recorded via impaling the cardiomyocytes in the BHM at day 22. Results 
showed that a majority of the cardiac cells present a ventricular action potential phenotype with 
however a high resting membrane potential of -42±2 mV along with fewer atrial and pacemaker 










































cells (Fig. 19). Ventricular and atrial cardiomyocytes were distinguished by their missing 
spontaneous depolarization in phase 4 of the action potential and their characteristic 
repolarization kinetics. Pacemaker cells demonstrated a clear spontaneous depolarization during 
phase 4 of the action potential. 
 
 
Figure 19: Electrophysiological properties of cardiomyocytes in BHM at culture day 22. 
Action potential recordings demonstrated predominant ventricular development in BHMs with some evidence for 
the presence of atrial and pacemaker phenotypes (n=27 cells in total from 9 BHMs). RMP: resting membrane 
potential; Vthreshold: threshold potential; MDP: maximum diastolic potential; PP: pacemaker potential; DDR: 
diastolic depolarization rate; APA: action potential amplitude; APD: action potential duration; n: number of cells 
demonstrating respective action potential phenotype. 
 
4.1.4.3 Cardiac ion channel and calcium homeostasis associated gene expression 
 
RNA-sequencing data revealed the expression of not only most common cardiac ion channels 
(SCN5A, HCN4, CACNA1C, and KCNH2), but also of canonical cardiac calcium homeostasis 
associated genes (RYR2, ATP2A2, PLN and CASQ2) in BHMs at day 22 (Fig. 20). 
Cell type Ventricular Atrial Pacemaker 
RMP (mV) -42±2 [-37, -32] 
Vthreshold  (mV) [-25, -19] 
MDP (mV) [-41, -30] 
PP (mV) [16, 11] 
DDR (mV/s) [99, 53] 
APA (mV) 64±2 [54, 44] [62, 45] 
APD20 (ms) 82±5  [38, 63] [73, 95] 
APD50 (ms) 112±6 [71, 89] [93, 137] 
APD90 (ms) 138±8 [107, 113] [108, 166] 
Frequency (Hz) 1±0,1 [1.3, 1.0] [3.4, 1.8] 
dV/dtmax (V/s) 13±3 [16, 6] [7, 6] 































Figure 20: Expression profile for cardiac ion channels and calcium homeostasis associated genes. 
RNA-sequencing data analyses showed an increased abundance of transcripts encoding (A) cardiac ion channels 
(SCN5a, HCN4, CACNA1C, KCNH2) and (B) calcium homeostasis associated genes (RYR2, ATP2A2, PLN, 
CASQ2) in BHM (n=4 BHMs/time point from three independent experiments). * P < 0.05 vs. -1d by ANOVA with 
Dunnett’s multiple comparison post-hoc test. SCN5a: sodium voltage-gated channel alpha subunit 5; HCN4: 
hyperpolarization activated cyclic nucleotide gated-potassium channel 4; CACNA1C: calcium voltage-gated 
channel subunit alpha1 C; KCNH2: potassium voltage gated-channel subfamily H member 2; RYR2: ryanodine 
receptor 2; ATP2A2: ATPase sarcoplasmic/endoplasmic reticulum calcium transporting 2; PLN: phospholamban; 
CASQ2: calsequestrin; BHM: bioengineered heart muscle; FPKM: fragments per kilobase of exon per million 
fragments. 











































































































































4.1.5 Continuous maturation of bioengineered heart muscle by day 60 
 
To investigate whether maturation in BHM is progressing with time, BHM from culture days 29 
and 60 were subjected to functional, morphological and molecular analyses and compared to 
day 22 BHM cultures. These extended cultures demonstrated the following functional 
properties: (1) cellular calcium (maximal FOC: 0.31±0.18 mN at day 60 vs. 0.21±0.07 mN at 
day 22; n=20; p<0.05) and –adrenergic stimulation (increase in FOC: 65±4% at day 60 vs. 
37±3% at day 22; n=20) as well as a right-shift of the calcium response curve (EC50 in mmol/L: 
0.6±0.2 at day 60 vs. 0.4±0.1 at day 22; n=20; Fig. 21 A and B); (2) decrease in spontaneous 
beating rate from 80±3 bpm at day 22 to 65±3 bpm at day 60 (n=20 respectively; Fig. 21C); (3) 
a significant drop not only in cross sectional area (CSA: 1±0.2 mm
2
 at day 60 vs. 1.9±0.2 mm
2
 
at day 22; n=8-10; p<0.05; Fig. 21D), but also in total BHM cell count and specifically the 







Figure 21: Functional, morphological and cell count analyses of BHMs in long-term cultures. 
(A) (i) Force of contraction (FOC) in response to increasing extracellular calcium concentrations measured under 
isometric conditions after 22, 29 and 60 days of culture; calcium concentrations with half maximal effect (EC50) are 
indicated with dotted lines (n=20 BHMs/time point). (ii) Inotropic response to β-adrenergic stimulation with 
isoprenaline (1 μmol/L) at 0.6 mmol/L calcium is represented in the bar graph (n=20 BHMs/time point). (B) 
Maximal FOC generated by BHMs after 22, 29, and 60 days of culture (n=20 BHMs/time point). * P < 0.05 vs. 
Day 22 by ANOVA with Dunnett’s multiple comparison post-hoc test (C) Beating rate recorded for BHMs after 
22, 29, and 60 days of culture (n=20 BHMs/time point). (D) Analysis of BHM cross sectional area after 22, 29, and 
60 days of culture (n=8 BHMs/time point). * P < 0.05 by ANOVA with Tukey’s multiple comparison post-hoc test 
(E) Cardiomyocyte (α-actinin) and non-myocyte (CD90) content in BHMs after 22, 29, and 60 days of culture 
(n=15-20 BHMs/time point). FOC: force of contraction; CSA: cross sectional area; Iso: isoprenaline. 
 
The drop in cardiomyocyte content and cross sectional area along with the increase in maximal 
force of contraction generated by the BHMs at day 60 suggested a markedly enhanced 
contractile performance of individual cardiomyocytes (4.6±1.3 nN/cardiomyocyte at day 60 vs. 
1.1±0.5 nN/cardiomyocyte at day 22; n=20; p<0.001; Fig. 22A) on the cellular level as well as 
per muscle bundle area on the tissue level (0.35±0.28 mN/mm
2
 at day 60 vs. 0.13±0.10 
mN/mm
2
 at day 22; n=8-11; p<0.05; Fig. 22B). At the ultrastructural level, no obvious 
differences of sarcomere assembly could be observed; at all time points well developed Z-, I- 
and A- bands were present (Fig. 22C). On the gross structural level, it appeared that day 60 































































































































Figure 22: Further functional and morphological maturation in long-term BHM cultures. 
(A) Maximal FOC per individual BHM cardiomyocyte (n=20 BHMs/time point). * P < 0.05 by ANOVA with 
Tukey’s multiple comparison post-hoc test. (B) Maximal FOC per cross sectional area (CSA; n=8-11 BHMs/time 
point) after 22, 29 and 60 days of culture. * P < 0.05 vs. Day 22 by ANOVA with Dunnett’s multiple comparison 
post-hoc test. (C) Ultrastructural analysis of sarcomeres in 22 and 60 day-old BHMs by transmission electron 
microscopy; scale bar: 500 nm. (D) Whole mount immunostaining of BHMs on day 22 and 63; α-actinin (green), 
actin (red) and DNA (blue); scale bar: 50 μm. Confocal images were recorded by James E. Hudson. FOC: force of 
contraction; CM: cardiomyocyte. 
 
Next, RNA-sequencing was performed on BHMs on day 29 and day 60 to investigate the 
transcriptional activity of cardiac genes possibly involved in the enhanced force of contraction. 
This analysis is challenging because of the differences in cardiomyocyte content in BHM at 
culture days 22, 29 and 60. Thus, we investigated the RNAseq data sets and found that ACTC1 
(cardiac actin) correlated closely with cardiomyocyte content (Fig. 23). For this reason, we used 
ACTC1 as a cardiomyocyte housekeeping gene to correct for differences in cardiomyocyte 
content in the following analysis of cardiomyocyte specific transcripts in BHM from culture 






Figure 23: Correlation of cardiomyocyte content and cardiac actin (ACTC1) in BHM. 
ACTC1 transcript abundance assessed by RNAseq is displayed on the ordinate. Cardiomyocyte content in BHM 
assessed after enzymatic dispersion on culture days 22, 29 and 60 is displayed on the abscissa. A correlation 
analysis by linear regression was performed (n=4 BHMs/time point). ACTC1: actin alpha cardiac muscle 1; BHM: 
bioengineered heart muscle; FPKM: fragments per kilobase of exon per million fragments. 
 
This analysis did indeed suggest, in agreement with the functional and morphological data, that 
further molecular maturation of cardiomyocytes in BHM occurred between culture days 22 and 
29 with stable levels of expression until day 60; evidenced by enhanced expression of TNNI3 
and MYH7 (Fig. 24). Expression of the latter gene was markedly enhanced while MYH6 
decreased, resulting in a further increase in MYH7/MYH6 transcript ratio (from 0.3±0.2 at day 
22 to 1.1±0.04 at day 60; n=4; p<0.05; Fig. 24) towards ratios observed in the adult heart (28±5; 
[kindly provided by Dr. Karl Toicher]) 
  






















Figure 24: Continuous molecular maturation in BHM with culture. 
Individual trajectory of genes transcribed in cardiomyocytes (TNNI3, MYH6 and MYH7). Correction of 
cardiomyocyte abundance was done by correlation of transcripts to ACTC1 as cardiomyocyte housekeeping gene 
for the data from BHM culture days 22-60 (red curve); uncorrected transcript abundance is depicted for comparison 
(black curve; n=4 BHMs/time point from three independent experiments). * P < 0.05 vs. 22d by ANOVA with 
Tukey’s multiple comparison post-hoc test. TNNI3: troponin I3 cardiac type; MYH6: myosin heavy chain 6; 
MYH7: myosin heavy chain 7; FPKM: fragments per kilobase of exon per million fragments. 
 
Similar analyses of transcripts encoding for proteins involved in cardiac muscle contraction 
(SCN5a, KCNH2 and HCN4; Fig. 25A) and calcium homeostasis (RYR2, CASQ2, and ATP2A2; 
Fig. 25B) confirmed the findings above and suggest that BHM maturation is a continuous 
process in BHM culture. 




























































Figure 25: Enhanced cardiac ion channel and calcium homeostasis associated gene expression. 
Individual trajectories of genes transcribed in cardiomyocytes involved in (A) cardiac ion channel for function 
(SCN5a, KCNH2 and HCN4) and (B) calcium homeostasis (RYR2, CASQ2, ATP2A2). Correction cardiomyocyte 
abundance was done by correlation of transcripts to ACTC1 as cardiomyocyte housekeeping gene for the data from 
BHM culture days 22-60 (red curve); uncorrected transcript abundance is depicted for comparison (black curve) 
(n=4 BHMs/time point from three independent experiments). * P < 0.05 vs. 22d by ANOVA with Dunnett’s 
multiple comparison post-hoc test. SCN5a: sodium voltage-gated channel alpha subunit 5; KCNH2: potassium 
voltage gated-channel subfamily H member 2; HCN4: hyperpolarization activated cyclic nucleotide gated-
potassium channel 4; RYR2: ryanodine receptor 2; CASQ2: calsequestrin; ATP2A2: ATPase 
sarcoplasmic/endoplasmic reticulum calcium transporting 2; ACTC1: actin alpha cardiac muscle 1; BHM: 
bioengineered heart muscle; FPKM: fragments per kilobase of exon per million fragments. 
 
  
































































































4.1.6 Evidence for cardiac-neuro crosstalk during BHM development 
 
In an effort to determine cell composition and associated biological processes in BHM, we 
evaluated our RNAseq data by an unbiased bioinformatic algorithm (SOTA; self-organizing tree 
algorithm; Hudson et al., in revision). This analysis identified 4 major processes, according to 
Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways, associated with BHM 
development: (1) cardiomyogenesis, (2) loss of potency, (3) neural crest development and (4) 
metabolism (Fig. 26). 
 
Figure 26: SOTA analysis of BHM transcriptomes.  
Bioinformatics analyses using self-organizing tree algorithm (SOTA) identified clusters with similar gene 
ontologies according to 4 biological processes: (1) cardiomyogenesis, (2) loss of potency, (3) neural crest and (4) 
metabolism. BHM: bioengineered heart muscle; FPKM: fragments per kilobase of exon per million fragments; 
SOTA: self-organizing tree algorithm; GO: gene ontology; KEGG: kyoto encyclopedia of genes and genomes; n: 
number of transcripts assigned specifically to individual clusters. 
 
 
The evidence of neural crest development in late BHM cultures was particularly interesting and 
prompted us to pay attention to the transcription of factors involved in neural development such 
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as NEUROD1, PAX6 and TH (Fig. 27A); all were upregulated and in particular the upregulation 
of TH as a pivotal enzyme in catecholamine synthesis in the sympathetic system supported the 
notion that neural crest developed. This was subsequently confirmed by stainings for TH in 
culture day 60 BHM (Fig. 27B); note that we did not observe any morphological evidence of 
ectodermal induction at earlier time points of BHM culture. The slightly enhanced PAX6 
transcription after day 8 in BHM development with concurrent increases in the TH and 
NEUROD1 (Fig. 27A arrow) did however suggest early, and so far unnoted, ectodermal activity 
in parallel to the functional maturation of BHM. More detailed morphological studies identified 
neuro-spheres, especially at the outer surface of BHM in close proximity to networks of well-







Figure 27: Molecular and morphological evidence for neural crest development in BHM. 
(A) Gene expression profiling identified canonical markers of ectoderm and neural crest development as precursors 
for the sympathetic nerve system (TH, NEUROD1 and PAX6) with a first sign of expression after culture day 8 and 
markedly enhanced expression on culture day 60 (n=4 BHMs/time point from three independent experiments). * P 
< 0.05 vs. -1d by ANOVA with Dunnett’s multiple comparison post-hoc test. Immunofluorescence staining of (B) a 
neurosphere in a day 60 BHM (TH: green, actin: (red), DNA: blue). Scale bar: 50 μm. (C) Overview of surface-
bound neurospheres in close proximity to well-organized cardiomyocyte bundles (actin: red, DNA: blue) in culture 
day 60 BHM. Scale bar: 500 μm. Boxes with striped lines indicate magnified regions. Scale bar: 20 μm. TH: 
tyrosine hydroxylase; NEUROD1: neuronal differentiation 1; PAX6: paired box 6; BHM: bioengineered heart 
muscle; DNA: deoxyribonucleic acid; FPKM: fragments per kilobase of exon per million fragments. 
 
In an attempt to investigate whether the identified neural crest-like structures could contribute 
functionally to BHM development, we sought to block the vesicular monoamine transporter 
(VMAT2) with reserpine to (1) prevent catecholamine reuptake and thus (2) enhance 
catecholamine release from functional sympathetic neurons; note that VMAT2 showed a similar 
expression profiles as the other neuronal markers (Fig. 28B). BHMs were first treated with 
reserpine for two weeks from culture day 46 to culture day 60 to deplete catecholamine stores 
and investigate whether its depletion would have a detrimental effect on BHM development. 
















































Isometric force measurements demonstrated no differences in BHM contractility and thus did 
not confirm our hypothesis (n=6 BHMs/group; Fig. 28C). However upon acute addition of 
reserpine to the tissues suspended in the organ baths, a progressive drop in beating rate was 
observed only in the chronically pretreated BHMs (red trace, n=3 BHMs/group; Fig. 28D) as 
opposed to the control tissues, which showed an increase in beating frequency (blue trace, n=3 
BHMs/group; Fig. 28D). Beating rate was stable in BHM that were niether chronically nor 
acutely treated with reserpine (black trace; n=3 BHMs/group; Fig. 28D). The increase in beating 
frequency in the not catecholamine depleted BHM suggests off-target effects or catecholamine 
leak. Conversely, the decrease in beating frequency in the catecholamine depleted BHM suggest 
a functional sympathetic nerve/neural crest component with a depletion of catecholamine stores 
in day 60 BHM. Further studies are needed to clarify the neural crest contribution and whether 








Figure 28: Evidence for a sympathetic component in day 60 BHM. 
(A) Schematic overview of the action of reserpine by blocking VMAT2 and inhibiting vesicular reuptake at the 
presynaptic terminal. Image adapted from www.studyblue.com. (B) Transcriptome profiling identified the 
expression of the vesicular monoamine transporter (VMAT2) in day 60 BHM. * P < 0.05 vs. -1d by ANOVA with 
Dunnett’s multiple comparison post-hoc test. (C) Depletion of catecholamine storage vesicles by 2 week reserpine 
(10 nmol/L) did not result in obvious differences in contractile function of BHM on culture day 60 (n=6 
BHMs/group). (D) Acute depletion of catecholamine stores while isometrically suspended in Tyrode’s solution at 
37 °C resulted in a decreased spontaneous beating frequency in reserpine pretreated BHM (red line) and an increase 
in beating frequency in untreated BHM (blue line); controls are in black (0.001% DMSO treated). (n=3 
BHMs/group). Tyr: tyrosine; VMAT2: vesicular monoamine transporter 2; NE: norepinephrin; ATP: adenosine 
triphosphate; NET: norepinephrin transporter; BHM: bioengineered heart muscle; FOC: force of contraction; 
























































































4.1.7 Applications of the BHM model in disease modeling and drug screening 
 
4.1.7.1 Disease modeling 
 
Studies from mice and chick models have demonstrated the importance of BMP signaling in 
cardiac cushion formation and myocardial differentiation of cardiac progenitors (Kruithof et al., 
2012; Wang et al., 2010). To test whether BMP inhibition would indeed cause a 
cardiomyogenesis defect in the absence of hemodynamic stresses, we added dorsomorphin (2 
μmol/L) and a more selective BMP-receptor (ALK2) inhibitor dorsomorphin homologue 1 
(DMH1, 2 μmol/L) during cardiac specification phase. The treatment started on culture day 6 
when early cardiac markers were already detected and thus fundamental processes of mesoderm 
induction were not influenced. The treatment continued until day 22 of BHM culture with 







Figure 29: Identification of faulty cardiomyogenesis in BHM under BMP inhibition. 
(A) Outline of the protocol with BMP-signaling blockade using dorsomorphin (2 µmol/L) or DMH1 (2 µmol/L) 
during culture days 6 to 22 of BHM development. Blockers were applied at concentrations established previously to 
be effective in biological models (Hao et al. [2008]; Hao et al. [2010]). (B) Chemical structures of Dorso (top) and 
DMH1 (bottom). (C) FOC examined under (i) increasing extracellular calcium concentrations measured on culture 
day 22 (n=8-12 BHMs/group). * P < 0.05 vs. Ctrl by two-way ANOVA with Bonferroni’s multiple comparison 
post-hoc test. (ii) Inotropic response to β-adrenergic stimulation with isoprenaline (1 μmol/L) at 0.6 mmol/L 
calcium is represented in the bar graph. * P < 0.05 vs. Ctrl by two-way ANOVA with Dunnett’s multiple 
comparison post-hoc test. (D) Flow cytometry for cardiomyocyte (α-actinin) and stromal cell (CD90) content on 
culture day 22 (n= 8 BHMs/group). * P < 0.05 vs. Ctrl by one-way ANOVA with Dunnett’s multiple comparison 
post-hoc test. (E) Immunofluorescence staining of cardiac muscle structures (α-actinin: green, actin: red, DNA: 
blue) of Dorso-treated BHMs vs. Control at culture day 22. Boxes with striped lines indicate magnified regions. 
Scale bar: 20 μm. Confocal Image is taken by James E. Hudson. Ctrl: control; Dorso: dorsomorphin; DMH1: 
dorsomorphin homologue 1; FOC: force of contraction; Iso: isoprenaline; CD90: Thy-1 cell surface antigen; d: 
days. 
 
On the functional level, at BHM culture day 22 both dorsomorphin and DMH1 treated tissues 
showed contractile dysfunction with a marked drop in force development (Maximal FOC in 
mN: 0.05±0.03 and 0.06±0.03 respectively vs. 0.2±0.04 for Ctrl; n=7-12; p<0.0001 vs. Ctrl; Fig. 
29C(i)) and inotropic response to isoprenaline stimulation (increase in FOC: 8±3% for dorso-
treated BHMs and 15±3% for DMH1-treated samples vs. 38±3% for Ctrl; n=7-12; p<0.0001; 
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Fig. 29C(ii)). Analyses of the cellular components showed a slight increase in the CD90
+
 







upon treatment with 
Dorso or DMH1 respectively vs. 0.45±0.13x10
6
 for Ctrl; n=7-12; p<0.001; Fig. 29D). 
Additionally, whole mount staining of BHM structures revealed impaired cardiac muscle 
formation upon BMP inhibition in line with the functional and cellular assessments (Fig. 29E). 
 
4.1.7.2 Drug screening 
 
Based on RNA sequencing data which revealed an increase in expression of many important 
cardiac ion channels by day 29 and 60, the next step was to test the functionality of these 
channels and consequently test whether BHM can be applied to identify the biological activity 
of classical ion channel blockers. Accordingly, BHMs at day 29 were treated with increasing 
concentrations (from 10
-5
 to 10 μmol/L) of (1) digitoxin (Na/K-ATPase inhibitor), (2) verapamil 
(L-Type Calcium channel blocker) and (3) E4031 (HERG blocker) and measured under 
isometric conditions in the presence/absence of electric field stimulation (3 Hz). BHM on 
culture day 29 were chosen due to the increase in overall tissue performance (i.e.: FOC, EC50 
shift in calcium response curve, elevated ion channel expression) compared to 22 day cultured 
BHM. 
 
Analyses of the inotropic (FOC; Fig. 30A), lusitropic (time-to-50% relaxation; Fig. 30B) and 
chronotropic (beating rate; Fig 30C) responses showed prototypic effects of the drugs; treatment 
with digitoxin lead to an increase in force development, time-to-50% relaxation and beating 
rate. Blocking the L-type calcium channel with verapamil resulted in the anticipated negative 
inotropic response. HERG (IKr) blockade with reference compound E4031 prolonged relaxation 
(Fig 30B) which resulted in a decreased beating rate (Fig. 30C) with no effect on force 
development (Fig. 30A). The latter observation was in line with action potential recordings of 
BHMs treated with E4031 (0.5 and 5 nmol/L) which demonstrated that IKr blockade resulted in 
significant increase in action potential duration (APD50: 272±17 ms with 0.5 nmol/L E4031; 





observed under basal conditions are indicative of BHM maturation at culture day 29 (Fig. 30D) 
in comparison to day 22 (Fig. 19). 
 
Figure 30: Identification of the biological activity of reference compounds in BHM. 
Effects of the positive inotrope digitoxin, the negative inotrope verapamil and the HERG inhibitor E4031 on (A) 
FOC, (B) time-to-50% relaxation, and (C) spontaneous beating rate in BHM at culture day 29 (n=4-6 BHMs/group) 
(D) Impaling electrode measurements of cardiomyocyte action potentials on BHM culture day 29 under HERG 
blockade with E4031. FOC: force of contraction; RMP: resting membrane potential; APA: action potential 
amplitude; APD: action potential duration. 
  
Basal 0.5 nM 5 nM 
RMP (mV) -45±5 -51±4 [-49, -56] 
APA (mV) 80±8 88±7 [85, 95] 
APD20 (ms) 142±6  205±9* [238, 244]* 
APD50 (ms) 198±7 272±17* [279, 286]* 
APD90 (ms) 259±16 406±62 [316, 691] 
Frequency (Hz) 0.9±0.3 0.7±0,03 [0.3, 0.4] 
dV/dtmax (V/s) 13±2 18±2 [11, 14] 
n 4 5 2 
Mean±SEM (except for individual data at 5 nM) *P<0.05 vs. Basal 
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4.2  Enhancing Maturation of Bioengineered Heart Muscle 
 
The collected data so far demonstrates that cardiac maturation in BHM is reminiscent of 
embryonic development. With a focus on BHM culture beyond the established 22-29 days, it 
was the aim to further delineate specific factors or conditions that may advance maturation of 
BHM systematically beyond the embryonic state. 
 
Since the time-course experiment confirmed progressive maturation of BHM, we hypothesized 
that BHM functionality can be further advanced by extended culture for up to 60 days with 
modulation of TGFβ-1 and insulin signaling as well as the basal medium composition. For these 
studies, BHMs were generated as described in 2.3.2 and culture was continued with 
modifications in the designated cardiac maturation phase (cultures days 13-60). 
 
4.2.1 Variation of TGFβ-1 stimulation during cardiac maturation 
 
Previously, we observed that TGFβ-1 (1 ng/mL) enhances cardiac maturation in BHM, 
evidenced by improved contractile function and an increase in MYH7/MYH6 transcript ratio 
(Hudson et al., in revision). This finding was scrutinized by testing the effect of different TGFβ-
1 concentrations, chronically added to the BHM culture (days 13 to day 22, 29 or 60) on BHM 
contractile function (Fig. 31A). 
 
Isometric force measurements by BHM culture day 22 revealed an increase in FOC in a 
concentration dependent manner, with no effect in the 0.3 ng/mL TGFβ-1 group and markedly 
enhanced contractility at higher TGFβ-1 concentrations (1-10 ng/mL) (Fig. 31B(i)). BHM cell 
composition was also affected with a decrease in cardiomyocyte and a concurrent increase in 
CD90 (fibroblast-like) cell content (Fig. 31B(ii)). Total cell number was not altered (Fig. 
31B(iii)), suggesting that TGFβ-1 enhanced FOC per cardiomyocyte in a concentration 
dependent manner (Fig. 31B(iv)). 
 
Next, we scrutinized whether extended TGFβ-1 (days 13-22 vs. day 13-29 of BHM culture) 





TGFβ-1 addition during culture days 13-22, extended stimulation (days 13-29) resulted in a 
concentration dependent negative effect on BHM contractility (Fig. 31C(i)). Cardiomyocyte 
content appeared further decreased (Fig. 31C(ii)) compared to the days 13-22 TGFβ-1 
stimulation protocol with however unaltered CD90 cell content. FOC per cardiomyocte was 
lower in the days 13-29 stimulation protocol as compared to FOC per cardiomyocyte in the days 







Figure 31: Functional maturation of BHMs by transient TGFβ-1 stimulation. 
(A) Outline of TGFβ-1 treatment protocol (0, 0.3, 1, 3 or 10 ng/mL) in BHMs added with every medium exchange 
during culture days 13 to day 22, 29 or 60. (B) TGFβ-1 stimulation during culture days 13-22: (i) FOC examined 
under increasing extracellular calcium concentrations (n=9-12 BHMs/concentration). * P < 0.05 vs. 0 ng/mL by 
two-way ANOVA with Bonferroni’s multiple comparison post-hoc test. (ii) Flow cytometry for cardiomyocyte (α-
actinin) and stromal cell (CD90) content on culture day 22 (n=10 BHMs/concentration). * P < 0.05 vs. 0 ng/mL by 
ANOVA with Dunnett’s multiple comparison post-hoc test. (iii) Total cell count (x10
6
) isolated from culture day 22 
BHM (n=11 BHMs/concentration). (iv) Maximal FOC per BHM cardiomyocyte (n= 10 BHMs/concentration). * P 
< 0.05 vs. 0 ng/mL by ANOVA with Dunnett’s multiple comparison post-hoc test. (C) TGFβ-1 stimulation during 
culture days 13-29: (i) FOC examined under increasing extracellular calcium concentrations (n=8-11 
BHMs/concentration). (ii) Flow cytometry for cardiomyocyte (α-actinin) and stromal cell (CD90) content on 
culture day 29 (n=6 BHMs/concentration). (iii) Total cell count (x10
6
) isolated from culture day 29 BHM (n=6 
BHMs/concentration). (iv) Maximal FOC per BHM cardiomyocyte (n= 6 BHMs/concentration). (D) TGFβ-1 (0, 1 
or 10 ng/mL) stimulation during culture days 13-60: (i) FOC examined under increasing extracellular calcium 
concentrations (n=4 BHMs/concentration). * P < 0.05 vs. 0 ng/mL by two-way ANOVA with Bonferroni’s 
multiple comparison post-hoc test. (ii) Flow cytometry for cardiomyocyte (α-actinin) content on culture day 60 
(n=4 BHMs/concentration). (iii) Total cell count (x10
6
) isolated from culture day 60 BHM (n=4 
BHMs/concentration). (iv) Maximal FOC per BHM cardiomyocyte (n=4 BHMs/concentration). TGFβ-1: 
transforming growth factor β-1; BHM: bioengineered heart muscle; CM: cardiomyocyte; FOC: force of 
contraction; CD90: Thy-1 cell surface antigen; d: days. 
 
To further define the effect of TGFβ-1 on BHM maturation, we next tested whether long-term 
stimulation from culture day 13 to culture day 60 with 1 or 10 ng/mL TGFβ-1 would have a 
beneficial or detrimental effect on BHM contractility (Fig. 31D(i)). Surprisingly and in contrast 
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(i)	 (ii)	 (iii)	 (iv)	





to our earlier short (day 13-22) and intermediate (day 13-29) term studies, we observed the best 
contractile performance in BHM not treated with TGFβ-1 at all. Cardiomyocyte content was in 
all conditions at ~20% (Fig. 31D(ii)) with a similar BHM cell count as observed on culture day 
22 and a ~50% reduced cell count as compared to culture day 29 (Fig. 31D(iii)). FOC per 
cardiomyocyte was unaffected (Fig. 31D(iv)). On the morphological level, TGFβ-1 treated 
tissues were significantly thinner as indicated by cross sectional area analyses (Fig. 32A), which 
is consistent with role of TGFβ-1 in extracellular matrix production. 
 
 
Figure 32: Cross sectional area of BHM under TGFβ-1 stimulation. 
Cross sectional area (CSA) of BHMs treated with TGFβ-1 (0, 1 or 10 ng/mL) during culture days 13-60 (n=4 
BHMs/concentration). * P < 0.05 vs. 0 ng/mL by one-way ANOVA with Tukey’s multiple comparison post-hoc 
test. TGFβ-1: transforming growth factor β-1; CSA: cross sectional area; FOC: force of contraction. 
 
Collectively, this series of experiments indicated the modulatory role of TGFβ-1 in early BHM 
maturation. This effect appears to be balanced out in long-term cultures potentially by intrinsic 
TGFβ-1 release. A pilot experiment with cultures for 29 and 60 days of transient TGFβ-1 (10 
ng/mL) stimulation only during culture days 13-22 was in agreement with this hypothesis (Fig. 
























Figure 33: Stabilization of long-term outcome by transient TGFβ-1 supplementation. 
(A) Outline of TGFβ-1 (10 ng/mL) temporary treatment protocol (from day 13 to day 22). (B) FOC examined 
under increasing extracellular calcium concentrations measured under isometric conditions in 29 and 60 days 
culture BHM. (n= 3 BHMs/concentration). TGFβ-1: transforming growth factor β-1; BHM: bioengineered heart 
muscle; FOC: force of contraction, d: days; Ctrl: control. 
 
4.2.2 Omission of insulin during cardiac maturation 
 
Insulin and insulin-like growth factor (IGF) are implicated in cardiomyocyte proliferation and 
hypertrophic growth in vivo (mouse embryos) (Li et al., 2011) and in vitro (hESC derived-
cardiomyocytes) (McDevitt et al., 2005). From previous studies in the lab we have learned that 
omitting insulin during mesoderm induction and cardiac specification (BHM culture days 0-13) 
leads to impaired cardiogenesis (Hudson et al., in revision). Thus, we tested whether insulin 
removal during “cardiac maturation” (BHM culture days 13 to 22, 29 or 60) would enhance or 
diminish BHM function. Isometric force measurements in these different groups did not identify 
differences in FOC (Fig. 34B/C/D (i)) despite a significant decrease in cardiomyocyte content in 
the absence of insulin (Fig. 34B/C/D (ii)). Total BHM cell content varied among these different 
groups depending on the BHM culture day with an overall increase by culture day 60 in the 
absence of insulin (Fig. 34B/C/D (iii)). Force per cardiomyocyte was markedly enhanced in the 
absence of insulin during short (day 13-22) and intermediate (day 13-29) term studies, but 
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similar in day 60 insulin treated and day 13-60 without insulin BHMs (Fig. 34B/C/D (iv)). 
Based on this observation it may be reasonable to withdraw insulin during cardiac maturation. 
 
Figure 34: Effect of insulin on BHM function. 
(A) Outline of insulin removal protocol in BHMs with every medium exchange during culture days 13-22, 13-29 or 
13-60. (B) Insulin removal during culture days 13-22: (i) FOC examined under increasing extracellular calcium 
concentrations (n=9 BHMs/group). (ii) Flow cytometry for cardiomyocyte (α-actinin) content on culture day 22 
(n=8 BHMs/group). * P < 0.05 vs. Ctrl by unpaired t-test. (iii) Total cell count (x10
6
) isolated from culture day 22 
BHM (n=9 BHMs/group). * P < 0.05 vs. Ctrl by unpaired t-test. (iv) Maximal FOC per BHM cardiomyocyte (n=7 
BHMs/group). * P < 0.05 vs. Ctrl by unpaired t-test. (C) Insulin removal during culture days 13-29: (i) FOC 
examined under increasing extracellular calcium concentrations (n=8 BHMs/group). (ii) Flow cytometry for 
cardiomyocyte (α-actinin) content on culture day 29 (n=7 BHMs/group). * P < 0.05 vs. Ctrl by unpaired t-test. (iii) 
Total cell count (x10
6
) isolated from culture day 29 BHM (n=7 BHMs/group). (iv) Maximal FOC per BHM 
cardiomyocyte (n=7 BHMs/group). * P < 0.05 vs. Ctrl by unpaired t-test. (D) Insulin removal during culture days 
13-60: (i) FOC examined under increasing extracellular calcium concentrations (n=7 BHMs/group). (ii) Flow 
cytometry for cardiomyocyte (α-actinin) content on culture day 60 (n=6 BHMs/group). * P < 0.05 vs. Ctrl by 
unpaired t-test. (iii) Total cell count (x10
6
) isolated from culture day 60 BHM (n=6 BHMs/group). (iv) Maximal 
FOC per BHM cardiomyocyte (n=6 BHMs/group). Ctrl: control; w/o Insulin: B27 minus insulin; BHM: 
bioengineered heart muscle; CM: cardiomyocyte; FOC: force of contraction; d: days. 
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4.2.3 Optimization of basal medium in long-term cultures 
 
RPMI1640 (composition in Appendix) has been described as the most commonly used medium 
in stem cell cultures and cardiomyocyte differentiation; it was also used in our original BHM 
protocol. In long term BHM cultures (>29 days) we frequently observed culture medium 
precipitations, which may be attributed to the high phosphate content and thus formation of 
insoluble calcium phosphate. We thus tested Iscove’s medium (composition in Appendix) as an 
alternative with similar amino acid and vitamin components, but more suitable calcium levels 
(1.2 mmol/L) and lower phosphate concentration (Fig. 35A).  
 
Figure 35: Consequences of basal medium on BHM function and cellularity. 
(A) Outline of the BHM cultivation protocol with RPMI or in Iscove’s medium during culture days 29-60. (B) FOC 
examined under increasing extracellular calcium concentrations measured under isometric conditions by culture 
day 60 (n= 11 BHMs/group). * P < 0.05 by two-way ANOVA with Bonferroni’s multiple comparison post-hoc test. 
(C) Total BHM cell count (x10
6
; n=11 BHMs/group). (D) Flow cytometry for cardiomyocyte (α-actinin) and 
stromal cells (CD90) on culture day 60 (n=11 BHMs/group). Ctrl: control; BHM: bioengineered heart muscle; 
CD90: Thy-1 cell surface antigen; d: days. 
 
A medium change from RPMI to Iscove’s between culture day 29 and 60 resulted in  markedly 
higher contractile forces (Fig. 35B). Total cell count was higher (not significant; Fig. 35C) and 
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In summary, BHM maturation is a continuous process. A surprising observation was the 
decrease in cardiomyocyte content despite enhanced function. Addition of TGFβ-1 (10 ng/mL) 
within a narrow time window (culture days 13-22), withdrawal of insulin during cardiac 
maturation (day 13 onwards) and replacement of RPMI with Iscove’s basal medium in long-
term cultures (day 29 onwards) were identified as useful modifications for robust BHM 
maturation. 
 
4.3 Replacement of BMP4 by a Small Molecule Mimic during Mesoderm Induction 
 
The BHM protocol was developed for robust application to multiple human PSC lines (Hudson 
et al., in revision). We however argued that replacing the protein growth factors with small 
molecules would further stabilize the BHM production process and focused on one of the 
growth factors, namely BMP4, with a pivotal role in mesoderm induction and known batch-to-
batch variation of its biological activity (Burridge et al., 2011; Hudson et al., 2012; Laflamme et 
al., 2007; Yang et al., 2008; Yao et al., 2006). The first step was to re-evaluate the optimal time 
window and concentration of BMP4 for mesoderm induction. This was followed by the 
screening for small molecule derivatives of the chalcone family in monolayer and BHM 
differentiation. 
 
4.3.1 Re-evaluation of the role of BMP4 for mesoderm induction in monolayer culture 
 
The evaluation of the BMP4 effect on mesoderm induction involved the testing of 0, 5 and 30 
ng/mL at different time-points of mesoderm induction (day 0 [24 hours]; day 0-1 [48 hours]; 
day 0-2 [72 hours]) with subsequent culture under standard conditions until day 22 (Fig. 36B). 
α-Actinin protein expression was assessed by flow cytometry to evaluate cardiomyocyte 
differentiation efficiency under the different conditions. Consistent with previous results 
(Hudson et al., in revision), 5 ng/mL BMP4 for at least 48 hours was optimal for the induction 
of cardiac mesoderm (Fig. 36B). Morphologically, BMP4 supplementation (5 ng/mL) for 72 
hours resulted in more synchronous beating activity. Subsequently, we defined the concentration 
dependent effect of BMP4 on concurrent cardiomyocyte and fibroblast-like cell (CD90
+
) 
induction capacity (Fig 36C). The cardiomyocyte and CD90
+





(19±3% and 8±1%, respectively; n=3) in the absence of BMP4. With the addition of 5 ng/ml 
BMP4, the population of both α-actinin and CD90
+
 cells increased markedly to 54±2% and 
20±5%, respectively (n=4). Upon a further increase of BMP4, cardiomyocyte number decreased 
significantly (12±3%), while the percentage of stromal cells doubled (39±4%; n=4). 
 
Figure 36: Effects of BMP4 on mesoderm induction in monolayer cultures. 
(A) Outline of the differentiation protocol (B in red indicates the time window for BMP4 supplementation). (B) 
Overview of the experimental conditions tested and the resulting effects on cardiomyocyte differentiation assessed 
by flow cytometry for α-actinin at monolayer culture day 22 (n=4 samples/group). * P < 0.05 vs. 0 ng/mL of BMP4 
by one-way ANOVA with Dunnett’s multiple comparison post-hoc test. (C) Overview of the experimental 
conditions tested and the resulting effects on cardiomyocyte and fibroblast-like cell differentiation assessed by flow 
cytometry for α-actinin and CD90 at monolayer culture day 22 (n=4 samples/concentration). * P < 0.05 vs. 0 
ng/mL of BMP4 by one-way ANOVA with Dunnett’s multiple comparison post-hoc test. HES2: human embryonic 
stem cell line 2; A: activin-A; B: bone morphogenetic protein 4; C: CHIR99021; F: fibroblast growth factor-2; 
IWP4: inhibitor of Wnt production 4; RPMI: Rosewell Park Memorial Institute basal medium; ASC: l-ascorbic 




Seeding	 Mesoderm	Induc on	 Cardiac	Specifica on	 Cardiac	Matura on	
-1d	 0d	 3d	 13d	 22d	
BMP4	(ng/mL)	Day	0	Day	1	 Day	2	












































































4.3.2 Re-evaluation of the role of BMP4 for mesoderm induction in BHM 
 
To study the effect of BMP4 on BHM development and function, we added 0, 1, 5, 10 or 30 
ng/mL BMP4  during mesoderm induction (Fig. 37A). Isometric force measurements at day 22 
revealed impaired functionality in the absence of BMP4 (Fig. 37B) associated with low 
cardiomyocyte content (3±1% α–actinin
+
 cells; n=6-8; Fig. 37C). Conversely, BHM 
demonstrated robust contractility upon addition of 5 ng/mL BMP4 during mesoderm induction 
(Fig. 37B) with a concurrently increased cardiomyocyte content (56±3%; n=6-8; Fig. 37C). 
Cardiomyocyte size was enhanced by 1.5-fold upon BMP4 addition even at low concentrations 
(Fig. 37D). Interestingly, higher concentrations of BMP4 (30 ng/mL) resulted in impaired BHM 
function and cardiac output (7±1% of α–actinin
+
 cells; n=6-8; Fig. 37C) with a 2-fold increase 
in CD90
+
 cells (63±3 vs 31±3% in 30 vs. 0 ng/mL BMP4 treated BHM, respectively; n=6-8; 
p<0.01; Fig. 37C). Collectively, this data confirmed the important role of mesoderm induction 







Figure 37: Effects of BMP4 on mesoderm induction in BHM. 
(A) Outline of BMP4 (0, 1, 5, 10 and 30 ng/mL) stimulation protocol during mesoderm induction in BHM. (B) 
Inotropic response to increasing extracellular calcium measured under isometric conditions in BHMs treated with 
the indicated BMP4 concentrations for mesoderm induction (n=6-8 BHMs/concentration). * P < 0.05 vs. 0 ng/mL 
of BMP4 by two-way ANOVA with Bonferroni’s multiple comparison post-hoc test (C) Flow cytometry analysis 
of cardiomyocyte (α-actinin) and stromal cells (CD90) content in day 22 BHM treated with the indicated BMP4 
concentrations during mesoderm induction (n=6-8 BHMs/concentration). * P < 0.05 vs. 0 ng/mL of BMP4 by one-
way ANOVA with Dunnett’s multiple comparison post-hoc test. (D) Cardiomyocyte (CM) size (side scatter median 
intensity normalized to 0 ng/mL BMP4) assessed by flow cytometry (n= 6-8 BHMs/concentration). * P < 0.05 vs. 0 
ng/mL BMP4 by ANOVA with Dunnett’s multiple comparison post-hoc test. BMP4: bone morphogenetic protein 
4; CD90: Thy-1 cell surface antigen; CM: cardiomyocyte; FOC: force of contraction; SSC-A: side scatter median 
intensity; d: days. 
 
4.3.3 Effect of BMP4 on gene expression profiles during BHM development 
 
qPCR analyses were performed to elucidate the role of BMP signaling for mesoderm induction 
and subsequent cardiac specification and maturation on the molecular level (Fig. 38A). In-line 
with the observations above, we noted that BMP4 reduced pluripotent marker OCT4 expression 
and enhanced MESP1 expression at day 3 as a sign for mesodermal commitment (Fig. 38B). 
NKX2-5 and ISL1 were enhanced by day 8 followed by an increase in the late cardiac marker 
MYL2 at day 22. The latter effects were more pronounced in the 5 ng/mL BMP4 group. The 
failure to enhance NKX2-5 in the presence of 30 ng/mL BMP4 was in line with the low 
cardiomyocyte content by day 22 (7±1 % of α–actinin
+
 cells, Fig. 37C) and the failure of BHM 
to contract (Fig. 37B). Collectively, these data confirm the essential role of BMP4 during the 
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Figure 38: Molecular consequences of BMP4 stimulation during mesoderm induction in BHM. 
(A) Outline of the BMP4 stimulation and culture protocol. (B) Relative gene expression of pluripotent marker 
OCT4, mesodermal marker MESP1, early cardiac markers NKX2-5 and ISL1 as well as the late cardiac marker 
MYL2 using qPCR. All data were normalized to GAPDH transcript abundance (n=3 BHMs/time point). * P < 0.05 
vs. 0 ng/mL BMP4 by two-way ANOVA with Dunnett’s multiple comparison post-hoc test. BMP4: bone 
morphogenetic protein 4; d: days; OCT4: octamer-binding transcription factor 4; MESP1: mesoderm posterior basic 
helix-loop-helix transcription factor 1; NKX2-5: NK2 transcription factor related locus 5; ISL1: islet 1; MYL2: 
myosin light chain 2; GAPDH: glyceraldehyde-3-phosphate-dehydrogenase; BHM: bioengineered heart muscle. 
 
 
4.3.4 Chalcones as potential small molecule activators of BMP signaling 
 
In a recent screen for small molecule activators of BMP signaling using luciferase assay under 
the Id1 promoter, four hit compounds from the family of flavonoids induced luciferase activity 
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greater than 50% relative to BMP4 (Vrijens et al., 2013). Two compounds were chalcones 
(isoliquiritigenin and 4’-hydroxychalcone) and the other two were flavones (apigenin and 
diosmetin). Only the former compounds activated BMP signaling via the phosphorylation of 
SMAD 1/5 as well as the expression of Id1 target genes in a concentration dependent manner. 
Based on these findings, we first investigated whether the two chalcones reported previously 
(4’-hydroxychalcone and isoliquiritigenin) could be used as BMP4 mimics in cardiac 
differentiation. We further performed an additional small scale efficacy screen with other 
available chalcones (cardamonin and hespiridine) and 15 in-house synthesized compounds 
(listed in Appendix) kindly provided by Prof. Dr. Dr. L. F. Tietze (Institute of Organic and 
Biomolecular Chemistry; Georg-August-Universität Göttingen). 
 
4.3.4.1 Screen for biological activity of commercially available chalcones and newly 
synthesized chalcones 
 
4’-hydroxychalcone and isoliquiritigenin were added at a concentration range from 0.0001 to 
100 μmol/L during mesoderm induction instead of BMP4 in a monolayer HES2 differentiation 
format (Fig. 39A). DMSO (0.001%) was added to the negative and positive (5 ng/mL BMP4) 
control to ensure comparability of the result (all chalcones were solubilized in DMSO). Cells 
were harvested at day 22 and analysed for the expression of α-actinin cardiac marker using flow 
cytometry (Fig. 39B). Increasing concentration of 4’-hydroxychalcone led to a gradual increase 
in the cardiomyocyte population which peaked at 10 μmol/L with comparable result to BMP4 
induction (% α-actinin
+
 cells: 43±5% for 10 μmol/L 4’-hydroxychalcone vs. 40±3% for 5 ng/mL 
BMP4; n=4-9; Fig. 39B). Isoliquiritigenin, on the other hand, demonstrated a biphasic effect on 
cardiac output which decreased first from 34±5% at 0.0001 μmol/L to 8±2% at 0.01 μmol/L and 
then increased again to 39±3% at 10 μmol/L. Note that both molecules induced cell death and 
consequential drop in cardiac cell population at 100 μmol/L indicating substance toxicity. In 
short, chalcones represent potential replacements of BMP4 during mesoderm induction with 
optimal concentration of 10 μmol/L. This concentration was used as a reference for the 






Figure 39: Preliminary screen of chalcones as BMP4 mimics for mesoderm induction. 
(A) Outline of the experimental protocol with the use of 4’-hydroxychalcone and isoliquiritigenin as BMP4 
replacements during mesoderm induction in a monolayer culture format. (B) Flow cytometry analysis of 
cardiomyocyte content (α-actinin) on culture day 22 (n=4-9 samples/concentration). Note that either chalcone 
exhibited cytotoxic effects at 100 μmol/L. All compounds were solubilized in DMSO (100%). DMSO alone served 
as negative (-) control. 5 ng/mL BMP4 with 0.001% DMSO served as positive (+) control.  * P < 0.05 vs. negative 
control by ANOVA with Dunnett’s multiple comparison post-hoc test. HES2: human embryonic stem cell line 2; 
A: activin-A; B: bone morphogenetic protein 4; C: CHIR99021; F: fibroblast growth factor-2; IWP4: inhibitor of 
Wnt production-4; RPMI: Rosewell Park Memorial Institute basal medium; ASC: l-ascorbic acid; d: days. 
 
 
Next, other commercially available chalcones such as cardamonin and hesperidine as well as 15 
newly synthesized chalcones (refer to Appendix for chemical structures) were tested at 10 
μmol/L for their capacity to induce cardiac differentiation when added for 72 hours during 
mesoderm induction (Fig. 40). Only isoliquiritigenin (in contrast to our first screen Fig. 39B) 
and hesperidin showed no effect on cardiac differentiation (Fig. 40). All other compounds 






Figure 40: Small scale screen of chalcones as BMP4 mimics during mesoderm induction. 
(Top) Chemical structures of compounds 4’-hydroxychalcone (A), isoliquiritigenin (B), cardamonin (C), and 
hesperidin (D). (Bottom) Flow cytometry analysis of cardiomyocyte (α-actinin) content in monolayer 
differentiation on culture day 22 (n=8-15 samples/compound). * P < 0.05 vs. – (negative control; DMSO 0.001%) 
by ANOVA with Dunnett’s multiple comparison post-hoc test. -: no BMP4; +: 5 ng/mL BMP4; compounds 1-15: 
Refer to Appendix for chemical structures. All compounds were solubilized in DMSO at 10 mmol/L and tested at 
10 μmol/L. 
 
4.3.4.2 Chalcones do not signal via SMAD or ERK phosphorylation 
 
BMP4 signals typically via SMAD1/5/8 phosphorylation (Fig. 41A). ERK phosphorylation was 
not affected by BMP4. Application of 4’-hydroxychalcone or 4-flouro-4’-methoxychalcone 
(compound 1 chosen randomly from the newly synthesized chalcones) did not phosphorylate 
SMAD1/5/8 and also did not alter ERK-phosphorylation. Thus, it appears that despite similar 
outcome with respect to cardiomyocyte differentiation, SMAD signaling may not be involved as 
mechanism of action associated with BMP4 mimics (Fig. 41). 
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Figure 41: SMAD and ERK phosphorylation in response to BMP4. 
HES2 cells were exposed to BMP4 (+; 5 ng/mL), 4-flouro-4’-methoxychalcone (compound 1; 10 μmol/L) and 4’-
hydroxychalcone (compound A; 10 μmol/L) during mesoderm induction in monolayer culture. (A) Western blot 
analyses of P-SMAD1/5/8, total SMAD1/5/8, P-ERK1/2 and total ERK1/2 in cell lysates at t=0 and 1 hour post-
treatment. GAPDH was used as a loading control. (B) Summary of Western blot data showing relative SMAD1/5/8 
and ERK1/2 phosphorylation to total SMAD1/5/8 (left) and total ERK1/2 (right; n= 3 samples/group). * P < 0.05 
vs. t=0 by one-way ANOVA with Dunnett’s multiple comparison post-hoc test. 0: t=0 hour; -: negative control; +: 
5 ng/mL BMP4; 1: 4-flouro-4’-methoxychalcone; A: 4’-hydroxychalcone; SMAD1/5/8: small body size mothers 
against decapentaplegic 1/5/8; P-SMAD1/5/8: phosphorylated-SMAD1/5/8; ERK1/2: extracellular signal regulated 
kinase 1/2; P-ERK1/2: phosphorylated-ERK1/2; GAPDH: glyceraldehyde 3-phosphate-dehydrogenase. 
 
4.3.5 Formation of bioengineered heart muscle with BMP mimics 
 
Despite several attempts to recapitulate the findings from the monolayer differentiation protocol 
of BHM culture, it was so far not possible to replace BMP4 by chalcones during mesoderm 
induction (so far tested: 4’-hydroxychalcone and 4-flouro-4’-methoxychalcone at 10 and 30 
































































chalcones in monolayer differentiation. This observation may result from differences in the 









Finding the appropriate model systems to recapitulate body functions and signaling pathways on 
the molecular, cellular and tissue level have always intrigued researchers. For this reason, 
several model systems have been developed and employed yet each still presents its own 
limitations. For instance, animal models have long served their purposes to provide insights on 
complex human disease mechanisms when human experimentation has not been feasible, but 
they remain limited by the often fundamental differences in physiology, pathology and 
pharmacology between human and animal, mostly rodent, models (Shanks et al., 2009). 
 
Cell cultures, and in particular monolayer cultures, reduce the complexity animal models and 
are thus excellent tools to study very specific molecular signaling events and their implications 
for cell behavior. However, traditional cell culture models lack the three-dimensionality of bona 
fide tissue, which creates a highly artificial context with questionable translatability to the 
relevant in vivo situation (Yin et al., 2016). Finally, the more recently developed 3D culture 
formats aim at overcoming the context dependent limitation of monolayer cultures, but also 
have to be considered (bio)artificial, albeit with in many cases closer resemblance to the target 
organ than classical cell cultures. With the introduction of human pluripotent stem cell models 
(Takahashi et al., 2007; Thomson et al., 1998), there are now great expectations that 
differentiation of those cells into defined lineages would advance our tool-set for studying 
human pathology in the dish. 
 
Our lab, with a focus on myocardial tissue engineering, has introduced several models of 
engineered heart muscle (EHM), including human EHM from embryonic (Soong et al., 2012; 
Tiburcy et al., 2014) and induced pluripotent stem cells (Streckfuss-Bomeke et al., 2013). The 
EHM technology makes use of differentiated cell populations and their culture in a three-
dimensional collagen type I hydrogel to generate beating heart muscle. More recently, a 
variation of the initially introduced tissue engineering concept (Langer and Vacanti, 1993) has 
been introduced, which is termed organoid cultures. Organoids take advantage of the capacity of 
undifferentiated pluripotent stem cells to develop into differentiated progeny if suspended either 





dimensional tissue-like aggregates (Gjorevski et al., 2014; Lancaster and Knoblich, 2014; Yin et 
al., 2016). Particular examples for the new organoid approaches include the so called mini-
brains (Lancaster et al., 2013), liver (Huch et al., 2013; Takebe et al., 2013), kidney (Takasato et 
al., 2014), prostate (Karthaus et al., 2014). Yet so far no data have been reported for the 
development of a cardiac organoid. 
 
This thesis builds on previous work by our group on the directed differentiation and self-
assembly of mouse and human pluripotent stem cells to form bioengineered heart muscle 
(BHM) in a single-step organoid approach (Hudson et al., in revision) as a model to simulate 
human heart development in a dish. The BHM model was inspired by embryonic development, 
following the hypothesis that hPSCs can assemble BHM if directed to differentiate into 
predominantly mesodermal cells with a major cardiomyocyte and fibroblast-like cell component 
in a collagen type I hydrogel to facilitate self-assembly. Developmental stimuli included: (1) 
Activin-A, BMP4, the GSK-3 inhibitor CHIR99021 for activation of the canonical Wnt-
pathway and FGF-2 (ABCF) for mesoderm induction, (2) the Wnt-inhibitor IWP4 for cardiac 
specification and (3) TGFβ-1 for cardiac maturation by specifically supporting stroma cell 
function. Adaptation from 0.4 to 1.2 mmol/L extracellular calcium during cardiac maturation 
and ascorbic acid were identified as additional supporting factors. This protocol resulted in 
robustly contracting BHM after 22 days in culture regardless of the tested human or non-human 
primate pluripotent stem cell starting population (Hudson et al., in revision). 
 
The main objectives of this thesis were: (1) a thorough characterization of the directed 
development in BHM, (2) the identification of interventions to further enhance BHM maturation 
and (3) a replacement of BMP4 with a small molecule BMP4 mimic. The main results of this 
thesis are summarized below: 
 
 Simulation of human heart development in bioengineered heart muscle 
 Evidence for functional neural crest contribution in long-term bioengineered heart 
muscle culture 
 Modeling of faulty cardiogenesis induced by BMP inhibition 





 Enhanced functional maturation of bioengineered heart muscle 
 Stimulation of mesoderm induction with a small molecule BMP pathway activator 
 
5.1 Simulation of Human Heart Development in Bioengineered Heart Muscle 
 
The basic BHM model is comprised of pluripotent stem cells in a collagen type I hydrogel. 
After a seeding phase (24 hour from day -1 to 0), mesoderm induction for 3 days is followed by 
induced cardiac specification for 10 days and cardiac maturation of BHM up to 60 days in this 
study. The differentiation protocol was adapted from a serum-free monolayer differentiation 
protocol which took in consideration the synergistic effect of BMP4 and Activin-A in inducing 
mesoderm from hPSCs (Hudson et al., 2012; Kattman et al., 2011; Lee et al., 2009). Based on 
previous studies showing the importance of Wnt/β-catenin signaling activation for optimal 
cardiac differentiation (Jackson et al., 2010; Lian et al., 2013; Paige et al., 2010), CHIR99021 
was introduced during mesoderm induction phase. Our observation on directed cardiac 
induction and the importance of proper mesoderm induction are supported by recent studies 
showing a combinatorial effect of BMP/Activin-A and canonical Wnt signaling (Kim et al., 
2015). Several studies have also demonstrated the implication of FGF signaling in the early 
cardiac induction of stem cells (Burridge et al., 2007; Elliott et al., 2011; Uosaki et al., 2011; 
Yang et al., 2008; Zhang et al., 2011) which appears to act primarily via ERK/MAPK pathway 
activation (Aouadi et al., 2006; Wu et al., 2010). Collectively, these observations and our own 
preliminary studies prompted us to define the ABCF protocol for mesoderm induction. 
 
Studies in the mouse model revealed the importance of Wnt/β-catenin deactivation during later 
stages of embryonic heart development (David et al., 2008; Kwon et al., 2007; Naito et al., 
2006). This was further supported by data from in vitro experiments, demonstrating that 
differentiation of primitive streak cells was enhanced towards cardiac specification upon 
inhibition of Wnt signaling (Hudson et al., 2012; Karakikes et al., 2014; Yang et al., 2008). 
Accordingly, we implemented the addition of Wnt-signaling inhibitor IWP4 for cardiac 







Processes underlying cardiomyocyte maturation are not well defined and most likely also 
include biophysical inputs (Liaw and Zimmermann, 2016). Mechanical stimulation to simulate 
hemodynamic loading was implemented during cardiac maturation in BHM together with 
TGFβ-1 stimulation to enhance ECM secretion by fibroblast-like HES progeny. The importance 
for dynamic mechanical loading for myocardial tissue engineering has been demonstrated 
previously (Zimmermann et al., 2006). Similarly, evidence for extracellular matrix/fibroblast 
stabilization by TGFβ-1 stemmed from earlier observations in our lab (Zimmermann et al., 
2002). The addition of ascorbic acid followed the rationale that collagen synthesis is dependent 
on its availability. 
 
RNA-sequencing analyses from BHM culture days -1, 3, 8, 13, 22, 29 and 60 confirmed that 
BHMs do indeed traverse through defined developmental stages. Mesoderm induction was 
characterized by the loss of the pluripotent marker OCT4 (Hough et al., 2009; Laslett et al., 
2007) and transient expression of early mesodermal markers such as MIXL1 (Tam and Loebel, 
2007), which in turn induces the expression of the master regulator of cardiovascular lineage 
specification MESP1 (Bondue et al., 2008; Bondue et al., 2011; David et al., 2008; Paige et al., 
2015). The transient expression of MESP1, peaking at day 3 in the BHM, appeared to be 
involved in the commitment of the mesodermally induced cells towards the cardiomyocyte 
lineage; this notion was supported by the expression of early cardiac progenitor markers 
including NKX2-5 and ISL1 (peak at day 8) and a concurrent increase in the expression of TBX5 
and ACTC1 (Behrens et al., 2013; Cai et al., 2003; Dierickx et al., 2012; Elliott et al., 2011; 
Moretti et al., 2006; Wu et al., 2006). The cardiac maturation phase was finally marked with the 
upregulation of late cardiac markers MYH7 and MYL2 (Beqqali et al., 2006). Taken together, 
time course gene expression profiling confirmed also on the molecular level that BHMs 
recapitulate defined stages of cardiac development. 
 
Enzymatic dissociation of BHMs at day 22 and subsequent analyses of cell composition using 
flow cytometry showed that our BHM differentiation protocol, unlike previous methodologies, 
did not involve directed differentiation of pluripotent stem cells to cardiomyocytes only 
(Burridge et al., 2015; Burridge et al., 2014; Burridge et al., 2011; Karakikes et al., 2014; Lian 
et al., 2015; Lian et al., 2013; Mummery et al., 2012), but also parallel development of stroma 





formation (Kensah et al., 2012; Naito et al., 2006; Nunes et al., 2013; Tiburcy et al., 2011; 
Zhang et al., 2013). Furthermore, traces of hematopoietic cells (marked by CD117 and CD45) 
and endothelial cells (marked by CD31) were observed, which may have originated from 
mesodermal cell population expressing T and MIXL1 (Davis et al., 2008; Kennedy et al., 2007; 
Lim et al., 2013; Murry and Keller, 2008). It is important to note that the inhibition of Wnt 
signaling with IWP4 starting day 3 (the peak of mesodermal marker expression) was introduced 
to favor cardiac mesoderm formation over hematopoietic and vascular differentiation (Lian et 
al., 2014; Murry and Keller, 2008; Nostro et al., 2008; Zhu et al., 2013). 
 
Knowing that myocardium, epicardium and endocardium are derived from a common precursor 
(Misfeldt et al., 2009; Witty et al., 2014), additional gene expression and morphological 
analyses were employed to screen for potential lineage diversification. Indeed, differential 
expression of CD31 and VE-Cadherin as well as WT1 and ALDH1A2 during BHM development 
suggested distinct endocardial and epicardial activity. Their contribution to the BHM formation 
process will need further investigations. 
 
BHMs started to beat by culture day 13 with continuous development into a highly synchronized 
contractile activity until culture day 22. Isometric force measurements revealed that BHMs 
displayed organotypic responses to preloading (Frank-Starling) and positive inotropy in 
response to increasing extracellular calcium concentrations and isoprenaline for β-adrenergic 
stimulation (Hirt et al., 2014; Schaaf et al., 2011; Soong et al., 2012; Streckfuss-Bomeke et al., 
2013; Tulloch et al., 2011). Impaling electrode measurements identified mostly ventricular 
working myocardium like cells in BHM at culture day 22. The generation of a mixture of 
cardiac cell types has been demonstrated previously (Hudson et al., 2012; Kehat et al., 2001; 
Mummery et al., 2003; Norstrom et al., 2006; Yoon et al., 2006). Note, however, that BHMs at 
day 22 possess immature action potential parameters as opposed to an adult ventricular 
cardiomyocyte (AVCM); such as automaticity, slower upstroke velocity (13 V/s for BHM vs. 
300 V/s for AVCM), higher membrane potential (-42 mV for BHM vs -85 mV for AVCM) and 
lower action potential amplitude (64 mV for BHM vs. 110 mV for AVCM). Yet the parameters 
recorded in BHM are higher than those recorded for fetal-like ventricular cardiomyocytes (He et 
al., 2003; Mummery et al., 2003; Rajala et al., 2011; Schram et al., 2002). Importantly, there 





and cardiac calcium homeostasis associated genes (RYR2, ATP2A2, PLN and CASQ2) by culture 
day 22 suggesting maturation of the electromechanical machinery in cardiomyocytes. Currently 
refined differentiation methods may allow for directed differentiation also into predominantly 
atrial and pacemaker-like cell rich BHMs or even BHM composed of defined cell mixtures 
(Birket et al., 2015; Devalla et al., 2015; Schwach and Passier, 2016). 
 
In line with the concept of continuous cardiomyocyte maturation, we observed a significant 
increase in maximal inotropic capacity and rightwards shift in calcium EC50 as well as 
responsiveness to β-adrenergic stimulation with concurrently enhanced network formation, 
comprised of elongated and striated cardiomyocytes. Collectively, we interpret the available 
data as evidence for enhanced cardiomyocyte maturation in BHM as compared to the maturation 
observed in extended monolayer cultures (Kamakura et al., 2013; Lundy et al., 2013). 
 
It is important to acknowledge that BHMs in the present format present lower absolute force as 
compared to the classical tissue engineering approach, using differentiated cardiomyocytes 
supported by typically collagen or fibrin matrix (Hirt et al., 2014; Kensah et al., 2012; Nunes et 
al., 2013; Schaaf et al., 2011; Soong et al., 2012; Streckfuss-Bomeke et al., 2013; Tiburcy et al., 
2011; Tulloch et al., 2011; Zhang et al., 2013). Also structurally, cardiomyocytes in BHM 
appear to be less mature as compared to cardiomyocytes in our classical engineered heart 
muscle (EHM) model (Soong et al., 2012; Tiburcy et al., 2014), which is developed from cell 
mixtures of different developmental stage (cardiomyocyte from 22 day monolayer 
differentiation as outlined here with fibroblasts from either foreskin [early postnatal] or skin 
from advanced aged donors). Despite this apparent technological shortcoming, BHM represent 
to our knowledge the only model, allowing for a recapitulation of embryonic to fetal human 
heart development from a homogenous pluripotent stem cell source. This may have particular 
advantages for example in the modeling and identification of embryonic heart toxicity, 
congenital heart disease and early potentially clinically not observable dysfunction in hereditary 
cardiomyopathies. Finally, also as an experimental tool for studies of physiological processes of 






5.2 Evidence for Functional Neuro-crest Contribution in Bioengineered Heart Muscle  
 
A surprising observation was the occurrence of a strong ectodermal molecular finger-print in 60 
day BHM cultures. This coincided with the development of variable cyst-like structures at the 
BHM surface. Force of contraction and BHM inner structure was not obviously affected by 
these morphological perturbations. Bioinformatics analyses revealed a strong activation of an 
ectodermal transcription program in day 60 BHM pointing to neural crest development. The 
neural crest contributes the sympathetic nerve system to the heart and is thought to invade the 
heart along vascular structures (Buitrago-Delgado et al., 2015; Donoghue et al., 2008; Hall and 
Gillis, 2013). BHM do not contain a vascular component, but exhibit neurosphere like structures 
only in day 60 cultures. These neurospheres co-stained with tyrosine hydroxylase (TH), being 
the rate limiting enzyme in catecholamine production in the sympathetic nerve system (Daubner 
et al., 2011; Molinoff and Axelrod, 1971). 
 
To test for the functional relevance of catecholamine production and storage from sympathetic 
vesicles, reserpine was applied chronically (for two weeks) and acutely in long term BHM 
culture. While chronic treatment, did not impart a notable effect on BHM development and 
basal function, there was evidence for a negative chronotropic effect by reserpine mediated 
blockade of VMAT as anticipated (Mandela et al., 2010; Metzger et al., 2002; Yamamoto et al., 
2007) likely as a consequence of depletion of catecholamine storage vesicles present only in the 
chronically conditioned BHM. Untreated BHM showed a trend towards a stable increase in 
beating rate which may be mediated by unspecific reserpine action on cholinergic stimulation or 
alternatively could suggest a constant catecholamine leak from less matured sympathetic 
neurons. This needs to be further investigated to elucidate the relevance of the “heart and brain” 
interaction in BHM. 
 
Neuroectoderm differentiation from hPSCs has been shown to be inhibited by BMP, Wnt and 
Activin signaling (Aubert et al., 2002; Murry and Keller, 2008; Ying et al., 2003). Detailed 
transcriptome analyses confirmed that there were already hints for ectoderm activation after 
culture day 8 (after mesoderm induction). Thus, it may be concluded that inhibition of 





notable that the surge in ectoderm expression with a strong neuro crest component occurred 
during a time window similar to in utero sympathetic nerve development (McCulley and Black, 
2012). Despite the evidence for cardiac mesoderm formation primarily in our BHM 
differentiation, there was minimal ectodermal contamination by day 22 marked by the presence 
of NEUROD1 expressing cells. Here we hypothesize that neural crest precursors remained 
dormant when most cells were mesodermally differentiated with an activation in long-term 
BHM culture (Buitrago-Delgado et al., 2015; Donoghue et al., 2008; Hall and Gillis, 2013). 
Considering the role of TGFβ-1 in regulation of neural crest cell proliferation (Chai et al., 2003; 
Sasaki et al., 2006), 1 ng/mL of TGFβ-1 supplemented in our prolonged BHM culture may have 
promoted neural development marked by elevated expression of PAX3 (Donoghue et al., 2008), 
SOX5 (Buitrago-Delgado et al., 2015) and more importantly a neuroectodermal specific marker 
SOX1 (Ying et al., 2003) by BHM culture day 60 (RNA sequencing data). 
 
These parallel interdependent processes of cardiac maturation and cardiac neurogenesis imply 
that BHMs follow a complex in utero-like development with a cardiac-neuro crosstalk. This 
needs to be further explored to dissect the role of neural crest cells in the functional maturation 
of cardiomyocytes not only in BHMs, but also in fetal heart development. 
 
5.3 Modeling of Faulty Cardiogenesis Induced by BMP Inhibition 
 
In an attempt to test the utility of BHMs in disease modeling, we sought to validate whether 
faulty cardiogenesis upon BMP inhibition can be induced in our BHM model. Studies in mouse 
and chick demonstrated the importance of BMP signaling in cardiac cushion formation 
(Kruithof et al., 2012) and myocardial differentiation of cardiac progenitors beyond mesoderm 
induction phase (Wang et al., 2010). Furthermore in collaboration with Dr. Zeidler and Prof. E. 
Wingender (Institute of Bioinformatics, University Medical Center Goettingen), we were able to 
collect evidence for enhanced SMAD signaling and inhibition of canonical Wnt signaling during 
cardiac specification of BHM development (Zeidler et al., 2016). 
 
Accordingly, the application of BMP inhibitors including dorsomorphin (Hao et al., 2008; Yu et 





BHM culture day 6) resulted in a block in cardiomyogenesis with subsequent contractile failure 
of BHM. Similar studies cannot be performed well in animal models, because a complete 
knock-out of BMP-receptors turned out to be embryonically lethal and conditional knock-outs 
tended to be confounded by hemodynamic disturbances likely due to malformation of the 
cardiac cushion and related heart valves (Gaussin et al., 2002; Kruithof et al., 2012; Yang et al., 
2006). 
 
Thus, we interpret our data as first evidence for a specific supportive effect of BMP-signaling at 
the cardiac progenitor cell stage for heart muscle formation. Note that BMP4 was only 
supplemented during mesoderm induction to stabilize endogenous BMP4 levels. BMP4 
expression peaks at day 8 of BHM development (RNAseq data - not shown) and thus inhibition 
of BMP-signaling with dorsomorphin or DMH1 starting from day 6 of BHM culture should 
have been maximally effective. In addition to the inhibition of the canonical BMP4 receptors 
ACVR1 (ALK2), BMPR1A (ALK3) and BMPR1B (ALK6) dorsomorphin also inhibits AMPK 
(Ki=109 nmol/L) and other signal pathways. The similar effect of the highly BMPR-selective 
inhibitor DMH1 and dorsomorphin suggests that indeed BMP-signaling is key for proper heart 
muscle specification and maturation in BHM. 
 
5.4 Proof-of-concept for the Application of BHM in Drug Screening 
 
Due to the finding that transcription of cardiac ion channel and calcium handling protein 
encoding genes and calcium sensitivity were more advanced towards the anticipated adult 
phenotype in culture day 29 BHM, we chose to investigate the biological activity of classical 
reference compounds (digitoxin, verapamil, E4031) with a focus on inotropy, lusitropy, and 
chronotropy in BHM of this stage and found that all investigated drugs caused the anticipated 
phenotype. This is in short: (1) for digitoxin an increase in contractile force; (2) for verapamil a 
decrease in contractile force and shortening of the action potentials with a concurrent increase in 
beating frequency; (3) for E4031 no effect on contractile force, but a prolongation of relaxation. 
The latter was associated with an increase in action potential duration (He et al., 2003). These 
data collectively suggest that BHM, despite its immaturity, can be used to identify the biological 





need to be extended to further scrutinize and compare the responsiveness of BHM to responses 
observed in bona fide human myocardium. 
 
5.5 Enhanced Functional Maturation of Bioengineered Heart Muscle 
 
We next postulated that BHM function can be further enhanced by optimizing the existing 
differentiation protocol by (1) re-evaluating the optimal TGFβ-1 stimulus (concentration and 
timing) for BHM formation, (2) omitting insulin stimulation, and (3) changing the basal medium 
from RPMI to Iscove’s medium especially for cardiac maturation in long term BHM culture. 
 
TGFβ-1 has been found to improve cardiomyogenic differentiation of hPSCs and cardiac 
progenitor cells (Goumans et al., 2008; Li et al., 2005). Yet, being a multifunctional growth 
factor, TGFβ-1 also stimulates synthesis of extracellular matrix components in stromal cells 
(Gooch et al., 2004; Muller-Pillasch et al., 1997; Nakamura et al., 1992; Sugiyama et al., 2013). 
This suggests a possible role of TGFβ-1 on both the cardiomyocyte and stromal cell population 
in BHMs. Here we defined that TGFβ-1 effectively supports BHM formation if added during 
culture days 13-22 at (1-10 ng/mL). Interestingly, long term stimulation for an additional week 
(until day 29) or an additional month (until day 60) resulted in inferior outcome with reduced 
contractile performance. A stronger compaction of BHM (reflected by a decrease in cross 
sectional area) under long term TGFβ-1 (10 ng/mL) suggests enhanced fibroblast functionality 
and potentially fibroblast to myofibroblast transformation. While the latter is interesting for 
example for disease modeling, additional studies would be needed to define the underlying 
mechanisms of the functional and structural deterioration. 
 
Insulin and insulin-like growth factor (IGF) signaling activate and mediate prosurvival and 
hypertrophic growth effects via the protein kinase B (Akt/PKB) pathway (Freund et al., 2008). 
Insulin was shown to on the one hand direct early cardiomyogenesis in mouse (McDevitt et al., 
2005; Naito et al., 2005) and on the other hand support EHM formation (Naito et al., 2006). 
Other groups reported that insulin inhibits early cardiomyogenesis (Freund et al., 2008; Lian et 
al., 2013; Lian et al., 2013; Xu et al., 2008). In a recent study (Lian et al., 2013), insulin indeed 





be rescued in the presence of Wnt signaling modulators as CHIR99021 and IWP4. The 
inhibitory effect of insulin signaling reported above may have seem overcome during early 
BHM development by the presence of Wnt pathway modulators. Here we tested whether insulin 
would be supportive or not during later phases of BHM differentiation and found that insulin is 
not required during cardiac maturation, i.e., from culture day 13 onwards. This appears to 
contrast previous studies showing the positive effects of insulin signaling on the proliferation of 
differentiated cardiomyocytes (Li et al., 2011; McDevitt et al., 2005; Xin et al., 2011). In BHM 
we could not find any evidence for enhanced cell proliferation under insulin stimulation. 
Whether insulin or IGF-1 via AKT mediated pro-survival signaling would be protective under 
“pathological” stimuli remains to be tested. 
 
In an attempt to reduce the precipitation of insoluble calcium phosphate in long-term cultures of  
RPMI treated BHMs, we investigated the use of Iscove’s medium during late stages of BHM 
maturation (from BHM culture day 29 upto day 60). Indeed the presence of suitable calcium 
levels (1.2 mmol/L) and lower phosphate content in Iscove’s medium resulted in enhaned 
contractile performance and increased total cell count in particular the cardiomyocyte content. 
 
Based on the above data, we now propose a refined long-term BHM cultivation protocol as 






Figure 42: Schematic outline of the optimized long-term BHM culture/maturation protocol. 
 
5.6 Stimulation of Mesoderm Induction with a Small Molecule BMP Mimic 
 
During embryogenesis, many signaling pathways work simultaneously which can have a 
positive feedback on one another at one point and conflict each other at other time points. For 
this reason, understanding the underlying mechanisms of these pathways are the key steps to 
targeting them for a more precise control over stem-cell differentiation into a particular lineage. 
Four major pathways are implicated in the early induction of mesoderm including 
TGFβ/Activin/Nodal, BMP, WNT and FGF (Burridge et al., 2007; Elliott et al., 2011; Hudson 
et al., 2012; Jackson et al., 2010; Kattman et al., 2011; Kim et al., 2015; Paige et al., 2010; Yang 
et al., 2008; Zhang et al., 2011). Several groups have reported that introducing BMPs at specific 
time points is crucial for the induction of cardiac mesoderm (Burridge et al., 2011; Hudson et 
al., 2012; Laflamme et al., 2007; Yang et al., 2008; Yao et al., 2006). Yet BMP is a recombinant 
protein which is both expensive and has a significant batch-to-batch variability in its biological 
activity (Peterson and Loring, 2012). For this reason, we postulated that small molecule 
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Prior to the screening for BMP4 mimics, we re-evaluated the temporal and concentration 
dependent effects of BMP4 on mesoderm induction and ultimately cardiomyocyte 
differentiation in a monolayer culture format. We first used the previously established 
concentration of 5 ng/mL BMP4 (Hudson et al., in revision) and varied the duration of 
stimulation from the first 24 to 48 and finally 72 hour of mesoderm induction. These 
experiments confirmed 48-72 hour as an optimal window for BMP4 stimulation. As to 
cardiomyocyte and concurrent fibroblast differentiation, 5 ng/mL were confirmed as optimally 
inductive, resulting in cell populations comprised of ~50% cardiomyocytes and ~20% CD90
+
 
fibroblast-like cells. Importantly, higher BMP4 concentrations resulted in markedly decreased 
cardiomyocyte and increase fibroblast content. Accordingly, BHM formation was optimally 
supported by 5-10 ng/mL BMP4. The slightly higher “tolerated” BMP4 concentrations (10 
ng/mL) in BHM may hint towards differences in monolayer vs. tissue availability of BMP4. 
 
The presence of Activin A which acts as a surrogate for NODAL and the Wnt agonist 
CHIR99021 in our culture format was enough to induce loss of pluripotency but not cardiac 
mesoderm induction evidenced by no increase in MESP1 in the absence of BMP4 during the 
designated mesoderm induction phase. Consequently, identification of the precise differentiation 
events would require further transcriptome studies for example to identify early mesodermal 
marker T and FLK1 for paraxial mesoderm which could give rise to hemopoetic and endothelial 
cell lineage as well as defintive endoderm in the absence of exogenous BMP4 (Martin-Puig et 
al., 2008; Murry and Keller, 2008; Orlova et al., 2016; Tam and Loebel, 2007). Moreover the 
induction of ectodermal cell population should be studied further by screens for NEUROD1, 
PAX6 and SOX1 expression (Aubert et al., 2002; Murry and Keller, 2008; Noisa et al., 2012; 
Ying et al., 2003). 
 
Finally, the available transcriptome data (MESP1 and ISL1 induction, but no NKX2-5 induction) 
could argue for development of extraembryonic mesoderm (Arnold and Robertson, 2009; 
Orlova et al., 2016) under high BMP4 concentrations (30 ng/mL). Collectively, this data 
confirm the important role of BMP4 for cardiac mesoderm induction in monolayer and BHM 
formats. This effect was time and concentration dependent with 5 ng/mL BMP4 added for 3 





cardiomyocyte and stromal cell differentiation. Both cell components are crucial for the 
formation of tissue engineered myocardium (Naito et al., 2006). 
 
The compelling evidence for the central role of BMP4 for mesoderm induction and subsequent 
cardiomyogenesis in vitro and in vivo (Burridge et al., 2015; Burridge et al., 2014; Hao et al., 
2008; Hao et al., 2010; Hudson et al., 2012; Karakikes et al., 2014; Lian et al., 2014; Lian et al., 
2015; Lian et al., 2013; Wang et al., 2011; Willems et al., 2009; Willems et al., 2011; Zhang et 
al., 2011) prompted us for the search for small molecule BMP4 signal pathway activators. A 
recent study, using a SMAD-response element to drive the expression of the luciferase gene, 
identified chalcones (Vrijens et al., 2013) as potential BMP signal stimulators. 
 
We tested 4 commercially available and 15 newly synthesized chalcones as BMP4 replacements 
during mesoderm induction first in monolayer culture. This identified 4’-hydroxychalcone and 
4-flouro-4’-methoxychalcone as equally effective at 10 µmol/L in the induction of 
cardiomyogenesis as BMP4 (5 ng/mL). Interestingly, both compounds apparently did not 
phosphorylate and thus activate SMAD1/5/8. Thus we concluded a differential so far undefined 
mechanism of action for the induction of BMP4 signaling in HES during mesoderm induction. 
 
The ultimate goal of a more defined BHM using BMP4 replacements could however not be 
reached since the tested chalcones (4’-hydroxychalcone and 4-fluoro-4’-methoxychalcone) 
failed to induce cardiac differentiation during BHM development even at higher concentrations 
(30 μmol/L). This may be attributed to the diffusion limits in the BHM as compared to 
monolayer cultures, stability of the compound within the collagen hydrogel and hydro-
philic/phobic properties of the compounds (El-Sayed and Gaber, 2015; Simmler et al., 2013). 
We will attempt to further modify the chemical structure of the identified hit molecules and 






6 Conclusion and Outlook 
 
In this thesis, the first detailed characterization of a novel cardiac organoid model, namely of 
bioengineered heart muscle (BHM), at the morphological, functional and molecular level is 
provided. A key observation was that BHM traverse through defined developmental stages and 
thus recapitulate human cardiomyogenesis from the embryonic to an early fetal stage. This 
allowed for the investigation of proper and faulty cardiomyogenesis as well as the 
responsiveness to classical pharmacological interventions targeting the heart. 
 
Despite not having reached adult-like maturity, we anticipate that BHM will be an attractive tool 
in mechanistic studies of congenital heart disease and hereditary cardiomyopathies. The guided 
differentiation into a multicellular mesodermal tissue with neuro-crest contribution at later 
stages of differentiation was an unanticipated observation, suggesting that advanced maturation 
may depend crucially on sympathetic inputs. Future studies will be directed to dissect the 
interplay of mesoderm and ectoderm in heart development and maturation. This will also 
include the further definition of “guiding” signaling pathways and the replacement of all growth 
factors by well-defined small molecules. The latter may finally also be of therapeutic relevance 
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Cell culture reagents 
 








KO-DMEM Invitrogen 10829-018 NA NA 500 mL 
KOSR Invitrogen 10828028 NA NA 128.2 mL 
L-glutamine Invitrogen 25030-024 200 mmol/L 2.6 mmol/L 6.4 mL 
MEM NEAA Invitrogen 11140-050 10 mmol/L 0.13 mmol/L 6.4 mL 
















10 μg/mL 10 ng/mL 50 μL 
       
Basal medium 
RPMI1640 Gibco 61870 NA NA 500 mL 




5.000 IU/mL and 
5 mg/mL 
100 IU/mL and 
100 μg/mL 
5 mL 
B27 supplement Gibco 17504044 NA 2 % 10 mL 





Invitrogen 14040 NA NA 40 mL 
FBS Gibco A15102 NA 20 % 10 mL 
Collagenase type I Sigma C0130 NA 1 mg/mL 100 mg 
       
Accutase mix 
DNase I stock Calbiochem 260913 1 mg/mL 20 μg/mL 2 mL 
Trypsin EDTA Gibco 1509-046 2.5% 0.025 % 1 mL 
Accutase solution Milipore SCR005 NA NA 97 mL 
       
10x DMEM 
Sterile water NA NA NA NA 5 mL 
DMEM powder Invitrogen 52100-039 NA 140 mg/mL 669 mg 
2x DMEM 




NA 140 mg/mL 17.5 mg/mL 2 mL 
       
BHM assembly 
(1x) 
Bovine collagen I 
LLC collagen 
solutions 




NA 17.5 mg/mL 2.9 μg/mL 34.2 μL 
NaOH Sigma 221465 0.1 mol/L 3 mmol/L 6.5 μL 







RPMI and Iscove media components 
 






Aminoacids    
Glycine 75 10 30 
L-Alanyl-Glutamine 217 446 584 
L-Alanine 89 - 25 
L-Arginine 174 200 84 
L-Asparagine 132 50 25 
L-Aspartic acid 133 20 30 
L-Cystine 240 50 - 
L-Glutamic Acid 147 20 75 
L-Histidine 155 15 42 
L-Hydroxyproline 131 20 - 
L-Isoleucine 131 50 105 
L-Leucine 131 50 105 
L-Lysine hydrochloride 183 40 146 
L-Methionine 149 15 30 
L-Phenylalanine 165 15 66 
L-Proline 115 20 40 
L-Serine 105 30 - 
L-Threonine 119 20 95 
L-Tryptophan 204 5 16 
L-Tyrosine 181 20 104.2 
L-Valine 117 20 - 
Vitamins    
Biotin 244 0.2 0.013 
Choline chloride 140 3 4 
D-Calcium pantothenate 477 0.25 4 
Folic acid 441 1 4 
Niacinamide 122 1 4 
p-Aminobenzoic acid 137 1 - 
Pyridoxine hydrochloride 206 1 4 
Riboflavin 376 0.2 0.4 
Thiamine hydrochloride 337 1 4 
Vitamin B12 1355 0.005 0.013 
i-Inositol 180 35 - 
myo-Inositol 180 - 7.2 
Inorganic salts    
Calcium nitrate 236 100 - 
Calcium chloride dihydrate 147 - 218.6 
Magnesium sulfate 246 100 200 
Potassium chloride 75 400 330 
Potassium nitrate 101 - 0.076 





Sodium chloride 58 6000 4505 
Sodium phosphate dibasic anhydrous 142 800 125 
Sodium pyruvate 110 - 110 
Sodium selenite 263 - 0.0173 
Other Components    
D-Glucose (Dextrose) 180 2000 4500 
Glutathione (reduced) 307 1 - 
Phenol Red 376.4 5 15 
HEPES 238 - 5958 
 
Reagents and solutions for isometric force measurements 
 
Stock solutions Molar mass Mass Volume of water Final concentration 
CaCl2 147.02 g/mol 165.57 g 500 mL 2.25 mol/L 
MgCl2 203.01 g/mol 106.83 g 500 mL 1.05 mol/L 
 
Three separate stocks are prepared and stored at 4 °C to be used for the preparation of the 
working Tyrode’s solution. 
Stock 1 
Tyrode’s Calcium 0.2 mmol/L  
NaCl 58.44 g/mol 175 g 
KCl 74.56 g/mol 10 g 
CaCl2 stock 2.25 mol/L 2.22 mL 
MgCl2 stock 1.05 mol/L 25 mL 
Adjusted with ddH2O  1000 mL 
 
Stock II 
NaHCO3 84.01 g/mol 50 g 
ddH2O 18 g/mol 1000 mL 
 
Stock III 
NaH2PO4 137.99 g/mol 5.8 g 






Tyrode’s working solution 
Stock I 80 mL 200 mL 
Stock II 76 mL 190 mL 
Stock III 20 mL 50 mL 
Glucose 2 g 5 g 
Ascorbic acid 100 mg 0.5 mg 
Adjust with ddH2O 2 L 5 L 
 
Tyrode’s working solution is prepared as indicated above just prior to isometric force 
measurements. It is important to note that 50% of the final ddH2O should be added first to 






Reagents for polyacrylamide gel electrophoresis (PAGE) 
 
Buffer Constituent Company Amount 
Laemmli buffer 
Tris HCl, pH 6.8 Carl Roth 2 mL 
Bromophenol Blue 0.5% AppliChem 0.5 mL 
SDS AppliChem 0.8 g 
Glycerin 100% AppliChem 1 mL 
β-Mercaptoethanol AppliChem 1 mL 
Adjusted with ddH2O  10 mL 
Separating gel (10%, 2x) 
ddH2O  4 mL 
Tris HCl (1.5 mol/L) pH 8.8 Carl Roth 2.5 mL 
Acrylamide 30% AppliChem 3.34 mL 
SDS 10% AppliChem 0.1 mL 
Ammonium phosphate 10% Life technologies 0.1 mL 
TEMED AppliChem 0.01 mL 
Collecting gel (6%, 2x) 
ddH2O  3.12 mL 
Tris HCl (0.5 mol/L) pH 6.8 Carl Roth 1.5 mL 
Acrylamide 30% AppliChem 1.2 mL 
SDS 10% AppliChem 0.06 mL 
Ammonium phosphate 10% Life technologies 0.06 mL 
TEMED AppliChem 0.006 mL 
Running buffer (10x) 
(diluted to 1x before use) 
Tris base Carl Roth 30.3 g 
Glycine AppliChem 144 g 
SDS AppliChem 10 g 









Buffer Constituent Company Amount 
Transfer Buffer (10x) 
Tris base Carl Roth 75.6 g 
Glycine AppliChem 74.4 g 
SDS AppliChem 15 g 
Adjust with ddH2O  1 L 
Transfer buffer with 
Methanol 
Transfer buffer (10x)  10 mL 
Methanol Carl Roth 20 mL 
Adjusted with ddH2O  100 mL 
TBST 
Tris HCl (1 mol/L) pH 7.6 Carl Roth 20 mL 
NaCl (5 mol/L) Carl Roth 33 mL 
Tween-20 Sigma-Aldrich 1 mL 
Adjusted with ddH2O  1 L 
Blocking solution 
BSA Sigma Aldrich 5 g 







RT-PCR and qPCR 
 
Table 1: Primers used in this study 
 














































qPCR 189 NM_002046.3 
 
Table 2: Conditions for qPCR reaction 
 
 For 1x reaction Final Concentration 
DEPC water 3.9 μL NA 
2x Syber Green 5 μL NA 
Primer (F) 0.05 μL 50 nmol/L 
Primer (R) 0.05 μL 50 nmol/L 
cDNA 1 μL NA 







Table 3: qPCR program used  
 
Cycle Step Temperature Time Cycles 
 50 °C 2 minutes 
1X 
Initial Denaturation 95 °C 10 minutes 
Denaturation 95 °C 15 seconds 
40 X Annealing 60 °C 1 minute 
Extension 95 °C 15 seconds 
Final extension 60 °C 15 seconds 
1X 







Table 4: Antibodies used in this study 
(FC-Flow cytometry, IF-Immunofluorescence, WB-Western blot) 
 
Antibody/Stain Company Cat No. Marker 
Dilution 
Factor 





Sigma A7811 Cardiomyocyte 
1:4000 FC 
1:1000 IF 
CD90 (mouse IgG) RnD systems MAB2067 Stromal cell 1:500 FC 
WT-1 (rabbit IgG) Abcam Ab89901 Epicardial cell 1:200 IF 
TH Millipore Ab152 Neurons 1:1000 IF 
GAPDH (mouse) Zytomed systems 607-0140 
GAPDH protein (37 
kDa) 
1:50000 WB 
SMAD1 (rabbit) Cell Signaling 9743 
Total SMAD 









ERK1/2 (rabbit) Cell Signaling 9102 
Total ERK1/2 
















Invitrogen A22283 NA 1:50 IF 





Dako P 0161 NA 1:10000 WB 
Anti-rabbit IgG 
HRP conjugated 







Chemical structure of 15 newly-synthesized chalcones (kindly provided by Prof. Dr. Dr. L. F. 





















    
   
      
Curriculum Vitae 
Farah S. Raad 
 
Personal Information 
Name:             Farah S. Raad 
Nationality:     Lebanese 
Gender:           Female 
Date of Birth:  October 9
th
, 1988 
Address:  University Medical Center Göttingen 
Georg-August Universität Göttingen 
  Robert-Koch str.40 
  37075 Göttingen 
  Deutschland 
Phone #:          004915736369981 
Email:             farah.raad@med.uni-goettingen.de 
 
Education 
October 2011 – present       Georg-August Universität Göttingen, Department of 
Pharmacology, Heart Research Center Göttingen 
(HRCG), University Medical Center Göttingen. 
Göttingen Germany 
Pursuing PhD in Molecular Medicine,  
                                             Expected Date of Graduation: June 2016 
 
September 2009-August2011  Jacobs University Bremen, Bremen Germany 
  M. Sc. in Nanomolecular Science (Chemistry) 
 
September 2006-June 2009  American University of Beirut, Beirut Lebanon 







July 2009-September 2009  University of Windsor, Windsor Canada 
  Intern in the Department of Chemistry 
Project based on the synthesis and characterization of 
Liquid Cyrstalline structures 
 
October 2007- June 2009  American University of Beirut, Beirut Lebanon 
Undergraduate Research Assistant in the Department of 
Chemistry 
Project based on 
 Synthesis and characterization of novel organic 
semiconductors. 
 Experimental analysis of the fluorescence effect of 
different anions on the fluorescence and 
absorbance of various sensors. 
 Synthesis and binding studies of novel organic 




 Separation, purification, cystallization, isolation and identification of organic and 
inorganic compounds. 
 Titration by fluorescence and UV-Vis. 
 Characterization using analytical techniques, e.g. NMR, IR, XRD, TGA. 
 
Biology-related skills: 
 Cell culture, molecular biology, cell biology, tissue engineering 
 Characterization using: flow cytometry, immunohistochemistry, western blotting, qPCR 
 
Computer skills: Good Knowledge of Microsoft Office, SciFinder, EndNote, Origin,  
Diamond, Graph Pad Prism, Adobe Illustrator 
 
Language skills: Arabic (mother tongue) 
       English (fluent) 








1. Raad FS, Moustafa RM, Jradi FM, Al-Sayah MH, Kaafarani BR (2010) Synthesis and 
Anion-Binding Studies of A Novel Pyrene Discotic. Tetrahedron. 66:2944-2952. 
 
2. Banerjee A, Raad FS, Vankova N, Bassil BS, Heine T, Kortz U (2011) 
Polyoxomolybdodiphosphonates: Examples Incorporating Ethylidenepyridines. Inorg. 
Chem. 50:11667. 
 
3. Eichhorn SH, Chen S, Ahmida M, Demenev A, Kayal H, Raad FS, Kaafarani BR, 
Patwardhan S, Grozema FC, Siebbeles LDA, Taerum T, Perepichka DF, Klenkler R 
(2011) A combined study of mesomorphism, optical, and electronic properties of donor-
acceptor columnar liquid crystals. Proceedings of SPIE. 8114:811402\1. 
 
4. Chen S, Raad FS, Ahmida M, Kaafarani BR, Eichhorn SH (2013) Columnar 
Mesomorphism of Fluorescent Broad-Shaped Quinoxalinophenanthrophenazine 
Derivatives with Donor-Acceptor Structure. Org. Lett. 15 (3):558-561. 
 
5. Al-Kadamany G, Bassil BS, Raad FS, Kortz U (2014) The Oxalato-Titanium-





. Journal of Cluster Science. 25:3 
 
6. El-Ballouli AO, Kayal H, Shuai C, Zeidan TA, Raad FS, Leng S, Wex B, Cheng S, 
Eichhorn SH, Kaafarani BR (2014) Lateral extension induces columnar mesomorphism 
in crucifix shaped quinoxalinophenanthrophenazines. Tetrahedron, 71:308-314. 
 
7. Zeidler S, Meckbach C, Tacke R, Raad FS, Roa A, Uchida S, Zimmermann WH, 
Wingender E and Gueltas M (2016). Computational Detection of Stage-Specific 
Transcription Factor Clusters during Heart Development. Front. Genet. 7:33. 
 
8. Hudson JE, Tiburcy M, Raad FS, Roa A, Muppala V, Döker S, Bartels I, Dressel R, 
Ziebolz D, Behr R, Zimmermann WH (2016) Directed Assembly of Human and Non-
Human Primate Heart Muscle from Embryonic and Induced Pluripotent Stem Cells. In 
Revision. 
 
9. Tiburcy M, Hudson JE, Balfanz P, Schlick S, Meyer T, Chang Liao ML, Levent E, 
Raad FS, Zeidler S, Wingender E, Riegler S, Wang M, Gold JD, Kehat I, Wettwer E, 
Ravens U, Dierickx P, Van Laake L, Goumans MJ, Toischer K, Hasenfuss G, Couture 
LA, Unger A, Linke W, Araki T, Neel B, Keller G, Gepstein L, Wu J and Zimmerman 
WH. (2016). Directed Maturation of Engineered Human Myocardium for Applications 








1. Raad FS, Jradi FM, Mustafa RM, Al-Sayah MH, Kaafarani BR (2008) Quinoxalino-
[2',3':9,10]phenanthro[4,5-abc]phenazine Fluorescent Sensors for Cations and Anions. 
4
th
 International Conference on Molecular Electronics (ElecMol08), Grenoble, France. 
 
2. Raad FS, Jradi FM, Mustafa RM, Al-Sayah MH, Kaafarani BR (2009) Fluorescent and 
Colorimetric Organic Sensors for Cations and Anions. Taibah International Chemistry 
Conference, Al-Madinah, Saudi Arabia. 
 
3. Kaafarani BR, Moustafa RM, Jradi FM, Degheili JA, Raad FS, El-Ballouli AO, Lucas 
L, Leng S, Zeidan TA, Wex B, Patra D, Al-Sayah MH, DeLongchamp DM, Jabbour 
GE, Cheng SZD (2009) Novel Pyrene-Based Discoids Exploited: Discovering Materials 
For Sensors, Electronic and Optoelectronic Devices. 238
th
 ACS National Meeting, 
Washington, DC, USA. 
 
4. Raad FS, Roa A, Hudson JE, Zimmermann WH (2014) Altering Tissue Functionality 
Using Growth Factors and Small Molecules in a Bioengineered Heart Muscle. Basic 
Science Meeting-DGK, Dusseldörf, Germany. 
 
5. Raad FS, Tiburcy M, Roa A, Zimmermann WH (2015) Simulating Human 
Myocardium in vitro. Fondation Leducq Meeting 2015, Trieste, Italy. 
 
6. Raad FS, Roa A, Hudson JE, Tiburcy M, Uchida S, Zimmermann WH (2016) 
Modeling Human Heart Development and Faulty Cardiogenesis in Bioengineered Heart 








Prof. Dr. Bilal R. Kaafarani 
Department of Chemistry 




Prof. Dr. S. Holger Eichhorn 
Department of Chemistry and Biochemistry 
University of Windsor 
Windsor, ON Canada 
E-mail: eichhorn@uwindsor.ca 
 
Prof. Dr. Ulrich Kortz 
Professor of Chemistry 
School of Engineering and Science 




Prof. Dr. Wolfram-Hubertus Zimmermann 
Department of Pharmacology and Toxicology 
Heart Research Center Göttingen (HRCG) 
University Medical Center Göttingen 
Georg-August Universität Göttingen 
Göttingen, Germany 
E-mail: w.zimmermann@med.uni-goettingen.de 
